[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 364
1. Lioi L, Galasso I, Lanave C, Daminati MG, Bollini R, Sparvoli F: Evolutionary analysis of the APA genes in the Phaseolus genus: wild and cultivated bean species as sources of lectin-related resistance factors? Theor Appl Genet; 2007 Nov;115(7):959-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition P. augusti, P. maculatus, P. microcarpus, and P. oligospermus showed the presence of the lectin-related alpha-amylase inhibitor-like (AIL) genes and alpha-AI activity.
  • The finding of detectable alpha-AI activity in species containing AIL genes suggests that exploiting APA genes variability in the Phaseolus genus may represent a valuable tool to find new members that may have acquired insecticidal activities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3820-5 [10759552.001]
  • [Cites] Plant Physiol. 1990 Jun;93(2):805-10 [16667540.001]
  • [Cites] Eur J Biochem. 2002 Jan;269(2):397-412 [11856298.001]
  • [Cites] Phytochemistry. 1996 Sep;43(1):57-62 [8987505.001]
  • [Cites] Theor Appl Genet. 2004 Apr;108(6):1098-102 [15067396.001]
  • [Cites] FASEB J. 1990 Nov;4(14 ):3198-208 [2227211.001]
  • [Cites] Theor Appl Genet. 2003 Sep;107(5):814-22 [12819911.001]
  • [Cites] Plant Mol Biol. 1994 Nov;26(4):1103-13 [7811969.001]
  • [Cites] Gut. 1995 Sep;37(3):353-60 [7590430.001]
  • [Cites] Plant Cell. 1991 Jan;3(1):1-9 [1824332.001]
  • [Cites] Eur J Biochem. 1984 May 15;141(1):97-104 [6723668.001]
  • [Cites] Curr Opin Plant Biol. 2005 Apr;8(2):129-34 [15752991.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Oct;86(20):7885-9 [2682631.001]
  • [Cites] Plant Physiol. 1972 Feb;49(2):187-9 [16657921.001]
  • [Cites] Planta. 1978 Jan;142(3):291-8 [24408192.001]
  • [Cites] Phytochemistry. 2001 Sep;58(1):59-66 [11524114.001]
  • [Cites] Biochim Biophys Acta. 1996 Jan 4;1292(1):15-22 [8547338.001]
  • [Cites] Plant Physiol. 1993 Apr;101(4):1341-8 [8310064.001]
  • [Cites] Food Chem Toxicol. 2003 Jan;41(1):21-7 [12453724.001]
  • [Cites] Mol Plant Microbe Interact. 2001 Aug;14(8):955-61 [11497467.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 3;1383(1):9-36 [9546043.001]
  • [Cites] Bioinformatics. 2001 Aug;17(8):754-5 [11524383.001]
  • [Cites] Biochim Biophys Acta. 2004 Feb 12;1696(2):181-90 [14871659.001]
  • [Cites] J Insect Physiol. 2000 Apr;46(4):393-402 [12770203.001]
  • [Cites] J Protein Chem. 2002 Jan;21(1):9-17 [11902670.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 17;1382(2):311-23 [9540803.001]
  • [Cites] Phytochemistry. 2006 Sep;67(18):2009-16 [16901522.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Plant Mol Biol. 2001 Mar;45(5):587-97 [11414617.001]
  • [Cites] Comput Appl Biosci. 1996 Dec;12(6):543-8 [9021275.001]
  • (PMID = 17701394.001).
  • [ISSN] 0040-5752
  • [Journal-full-title] TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
  • [ISO-abbreviation] Theor. Appl. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phytohemagglutinins; 0 / Plant Lectins; 0 / alpha-amylase inhibitor, Phaseolus vulgaris; EC 3.2.1.1 / alpha-Amylases
  •  go-up   go-down


2. Samocha KE, Lim JE, Cheng R, Sokoloff G, Palmer AA: Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines. Genes Brain Behav; 2010 Oct;9(7):759-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines.
  • Humans with neurological and psychiatric disorders, including schizophrenia, obsessive-compulsive disorder and Huntington's disease, exhibit a reduction in PPI.
  • In order to elucidate the genes involved in sensorimotor gating, we phenotyped 472 mice from an F(2) cross between LG/J × SM/J for PPI and genotyped these mice genome-wide using 162 single nucleotide polymorphism (SNP) markers.
  • We also phenotyped 135 mice from an F(34) advanced intercross line (AIL) between LG/J × SM/J for PPI and genotyped them at more than 3000 SNP markers.
  • Inclusions of data from the AIL mice reduced the size of several of these QTLs to less than 5 cM.
  • These results will be useful for identifying genes that influence sensorimotor gaiting and show the power of AIL for fine mapping of QTLs.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Genes, Brain and Behavior © 2010 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.
  • [Cites] Biol Psychiatry. 1993 Feb 15;33(4):298-301 [8471686.001]
  • [Cites] Arch Gen Psychiatry. 1992 Mar;49(3):206-15 [1567275.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Br J Med Psychol. 1961;34:103-16 [13773940.001]
  • [Cites] Biol Psychiatry. 2005 May 15;57(10):1153-8 [15866555.001]
  • [Cites] Genet Res. 2005 Jun;85(3):211-22 [16174340.001]
  • [Cites] Genetics. 2005 Dec;171(4):1895-904 [15998716.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Arch Gen Psychiatry. 2007 Nov;64(11):1242-50 [17984393.001]
  • [Cites] PLoS Biol. 2007 Nov;5(11):e297 [18001149.001]
  • [Cites] Biol Psychiatry. 2007 Dec 15;62(12):1418-22 [17481589.001]
  • [Cites] Pharmacol Biochem Behav. 2008 Oct;90(4):525-33 [18513787.001]
  • [Cites] Biol Psychiatry. 2009 Mar 1;65(5):401-8 [19013555.001]
  • [Cites] Schizophr Res. 2009 Jun;111(1-3):182-91 [19351577.001]
  • [Cites] Neurosci Res. 2009 Nov;65(3):259-62 [19660506.001]
  • [Cites] Genes Brain Behav. 2009 Nov;8(8):806-16 [19694817.001]
  • [Cites] Genetics. 2010 Jul;185(3):1033-44 [20439773.001]
  • [Cites] Behav Neurosci. 2000 Apr;114(2):374-88 [10832798.001]
  • [Cites] Am J Psychiatry. 2000 Oct;157(10):1660-8 [11007721.001]
  • [Cites] Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54 [11549216.001]
  • [Cites] Biol Psychiatry. 2001 Sep 15;50(6):418-24 [11566158.001]
  • [Cites] Genome Res. 2002 Apr;12(4):618-26 [11932246.001]
  • [Cites] Neuropsychopharmacology. 2002 Nov;27(5):765-81 [12431851.001]
  • [Cites] Psychopharmacology (Berl). 2003 Jan;165(3):270-9 [12426667.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Behav Neurosci. 2003 Aug;117(4):716-27 [12931957.001]
  • [Cites] J Neurosci Res. 2003 Nov 15;74(4):562-9 [14598300.001]
  • [Cites] Neurosci Lett. 2003 Dec 15;353(1):45-8 [14642434.001]
  • [Cites] Psychopharmacology (Berl). 2004 Aug;174(4):452-62 [15300359.001]
  • [Cites] Genome Res. 2004 Sep;14(9):1806-11 [15342563.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):192-200 [7876851.001]
  • (PMID = 20597988.001).
  • [ISSN] 1601-183X
  • [Journal-full-title] Genes, brain, and behavior
  • [ISO-abbreviation] Genes Brain Behav.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / T32 MH020065; United States / NIMH NIH HHS / MH / R01 MH079103; United States / NIDA NIH HHS / DA / R01 DA021336; United States / NIDA NIH HHS / DA / R21DA024845; United States / NIDA NIH HHS / DA / R01DA021336; United States / NIMH NIH HHS / MH / T32MH020065; United States / NIDA NIH HHS / DA / R21 DA024845
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ NIHMS490035; NLM/ PMC3749925
  •  go-up   go-down


3. Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J: Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol; 2008;47(6):1029-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effect measures were quality-adjusted life-years (QALY) and life-years gained (LYG).
  • RESULTS: The evaluation assessed rituximab maintenance therapy to be associated with an incremental cost per QALY gained of euro 12,600 and an incremental cost per LYG of euro 11,200.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cost-Benefit Analysis. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Quality-Adjusted Life Years. Remission Induction. Rituximab. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607857.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U: Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess; 2010;6:Doc05
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESEARCH QUESTIONS: What is the long-term clinical effectiveness (reduction in lifetime risk of cervical cancer and death due to cervical cancer, life years gained) of HPV testing and what is the cost-effectiveness in Euro per life year gained (LYG) of including HPV testing in primary cervical cancer screening in the German health care context?
  • RESULTS: In the base case analysis screening resulted in a 53% to 97% risk reduction for cervical cancer with a discounted ICER between 2,600 Euro/LYG (cytology alone every five years) and 155,500 Euro/LYG (Annual cytology age 20 to 29 years, and annual HPV age 30 years and older).
  • An optimal strategy may be biennial HPV testing age 30 years and older with biennial cytology at age 25 to 29 years (ICER of 23,400 Euro/LYG).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21289878.001).
  • [ISSN] 1861-8863
  • [Journal-full-title] GMS health technology assessment
  • [ISO-abbreviation] GMS Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3010885
  • [Keywords] NOTNLM ; DNA / HPV / HPV-DNA diagnosis / Health Technology Assessment / Markov model / cancer / carcinoma / cervical carcinoma / cervix / cervix of uterus / cost-effectiveness / cytology / decision-analytical modelling / diagnosis / early finding / effectiveness / health economic evaluation / human papillomavirus / long-term effectiveness / meta-analysis / primary screening / screening / systematic review / test
  •  go-up   go-down


5. Bonardi S, Paris A, Bassi L, Salmi F, Bacci C, Riboldi E, Boni E, D'Incau M, Tagliabue S, Brindani F: Detection, semiquantitative enumeration, and antimicrobial susceptibility of Yersinia enterocolitica in pork and chicken meats in Italy. J Food Prot; 2010 Oct;73(10):1785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All isolates were tested for yadA, ail, inv, ystA, and ystB virulence sequences.
  • The yadA gene was detected in two strains (3.7%) isolated from chicken samples: one Y. enterocolitica 2/O:9 yadA+ ail+ ystA+, and one Y. enterocolitica 1A/O:7,8-8-8,19 yadA+ inv+ ystB+.
  • Two (3.7%) 2/O:9 strains, isolated from pork products, were ail+ ystA+.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067665.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


6. Kawai N, Miyake K, Nishiyama Y, Yamamoto Y, Sasakawa Y, Haba R, Kushida Y, Tamiya T, Nagao S: FDG-PET findings of the brain in lymphomatoid granulomatosis. Ann Nucl Med; 2006 Dec;20(10):683-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET findings of the brain in lymphomatoid granulomatosis.
  • Although 18F-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) did not display a significant increase in FDG accumulation in the bilateral frontal and parietal white matter, kinetic analysis of this scan showed increased hexokinase activity in the lesions compared to the unaffected occipital white matter.
  • Diagnosis was made by open biopsy of the right frontal lobe and pathologic specimen was positive for lymphomatoid granulomatosis (LYG).
  • The patient received high-dose methotrexate with CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisolone) chemotherapy and follow-up MRI showed improvement of the lesions.
  • [18F]FDG-PET study with kinetic analysis may be useful to diagnose LYG in the central nervous system.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain / radionuclide imaging. Brain Neoplasms / drug therapy. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphomatoid Granulomatosis / drug therapy. Lymphomatoid Granulomatosis / radionuclide imaging

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385307.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Ferrara F, Ravasio R: Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig; 2008;28(1):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The model provided an estimate of mean survival (life-years gained [LYG]) and mean costs (direct medical costs) over a period of 3 years.
  • RESULTS: The LYG with the R-CHOP regimen was higher (2.697 LYG per patient) than with the CHOP regimen (2.517 LYG per patient).
  • Sensitivity analyses showed that the incremental cost-effectiveness ratios per LYG for complete response at 5 months (16,816.00 euro) and for relapse-free survival at 3 years (11,967.12 euro) were below the internationally accepted threshold (50,000 euro).
  • Furthermore, for survival at 3 years, R-CHOP was confirmed as the dominant therapy (lower expected mean costs, higher number of LYG).
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antibodies, Monoclonal, Murine-Derived. Cost-Benefit Analysis. Cyclophosphamide / administration & dosage. Cyclophosphamide / economics. Cyclophosphamide / therapeutic use. Decision Trees. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Doxorubicin / economics. Doxorubicin / therapeutic use. Humans. Injections, Intravenous. Prednisone / administration & dosage. Prednisone / economics. Prednisone / therapeutic use. Prognosis. Reproducibility of Results. Rituximab. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / economics. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Drug Investig. 2008;28(7):461-2; author reply 462-3 [18544006.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82 [15361313.001]
  • [Cites] Postgrad Med J. 1999 Jan;75(879):2-6 [10396578.001]
  • [Cites] Risk Anal. 1995 Jun;15(3):369-90 [7604170.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2558-66 [17169800.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Pharmacoeconomics. 2004;22 Suppl 4:5-10 [15876007.001]
  • [Cites] Ann Hematol. 2007 Feb;86(2):107-15 [17103169.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:241-62 [12446426.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1605-9 [15370212.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):194-202 [15693788.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Haematologica. 2002 Aug;87(8):816-21 [12161357.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • [Cites] Cancer Invest. 2006 Oct;24(6):593-600 [16982464.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18081361.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


8. Birger J: What ails health stocks? Fortune; 2005 Nov 14;152(10):219-20, 223-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What ails health stocks?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300369.001).
  • [ISSN] 0015-8259
  • [Journal-full-title] Fortune
  • [ISO-abbreviation] Fortune
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


9. Gorelick KJ: What ails the FDA? N Engl J Med; 2005 Jun 16;352(24):2553-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What ails the FDA?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2005 Mar 17;352(11):1063-6 [15784660.001]
  • (PMID = 15958814.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


10. Thavorn K, Chaiyakunapruk N: A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control; 2008 Jun;17(3):177-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURE: Cost per life year gained (LYG) attributable to the smoking cessation programme.
  • This finding provides important information for health policy decision-makers when determining the magnitude of resources to be allocated to smoking cessation service in community pharmacy.
  • [MeSH-minor] Adult. Cost-Benefit Analysis / statistics & numerical data. Female. Heart Diseases / economics. Humans. Lung Neoplasms / economics. Male. Markov Chains. Middle Aged. Program Evaluation. Pulmonary Disease, Chronic Obstructive / economics. Thailand

  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285385.001).
  • [ISSN] 1468-3318
  • [Journal-full-title] Tobacco control
  • [ISO-abbreviation] Tob Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Macedo A, Monteiro I, Andrade S, Cirrincione A, Ray J: [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]. Acta Med Port; 2010 May-Jun;23(3):475-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Custo-efectividade de trastuzumab no tratamento de doentes com cancro da mama em estádios iniciais em Portugal.
  • INTRODUCTION: Despite the important advances observed in the last 25 years in the comprehension of the clinical and biological nature of breast cancer and its treatment, this disease remains a significant cause of cancer morbidity and mortality worldwide.
  • The incremental cost-effectiveness ratios per life year gained (LYG) and per quality adjusted life year (QALY) gained were estimated.


12. Itoh T, Umekawa K, Rensha K, Minami K, Shoji S, Kitaichi M, Hirata K: [A case of grade I lymphomatoid granulomatosis detected as a solitary lung nodule in a health examination]. Nihon Kokyuki Gakkai Zasshi; 2008 Jan;46(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of grade I lymphomatoid granulomatosis detected as a solitary lung nodule in a health examination].
  • The pathologic diagnosis of the resected lung was lymphomatoid granulomatosis/angiocentric immunoproliferative lesion (LYG/AIL), grade I.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260311.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Paudel KP, Kumar S, Meur SK, Kumaresan A: Ascorbic acid, catalase and chlorpromazine reduce cryopreservation-induced damages to crossbred bull spermatozoa. Reprod Domest Anim; 2010 Apr;45(2):256-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proportion of acrosome intact live (AIL), acrosome intact dead, acrosome reacted live and acrosome reacted dead sperm was assessed in fresh, equilibrated and frozen-thawed semen.
  • In cryopreserved semen, the values of AIL spermatozoa, HOSST response, hyaluronidase and acrosin activity were reduced by 53%, 47%, 34% and 54%, respectively from their initial values in fresh semen.
  • The percentage of AIL sperm was significantly (p < 0.05) higher in ascorbic acid, catalase and ascorbic acid + chlorpromazine incorporated groups compared with the control.

  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. Chlorpromazine .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032433.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cryoprotective Agents; EC 1.11.1.6 / Catalase; PQ6CK8PD0R / Ascorbic Acid; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


14. Warolin C: [The opiate pharmacopeia in France from its origins to the 19th century]. Rev Hist Pharm (Paris); 2010 Apr;58(365):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sydenham's laudanum (1683) was adopted by ail the pharmacopeias.
  • Seguin, but above ail the German pharmacist Sertürner (in 1805 and 1817) isolated morphine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20533811.001).
  • [ISSN] 0035-2349
  • [Journal-full-title] Revue d'histoire de la pharmacie
  • [ISO-abbreviation] Rev Hist Pharm (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 8008-60-4 / Opium
  •  go-up   go-down


15. Joseph R, Chacko B, Manipadam MT, Sureka J, Cherian VK, John GT: Pulmonary lymphomatoid granulomatosis in a renal allograft recipient. Transpl Infect Dis; 2008 Feb;10(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphomatoid granulomatosis in a renal allograft recipient.
  • Lymphomatoid granulomatosis (LYG) is a rare multisystemic angiocentric lymphoproliferative disease, which can masquerade as necrotic tissue.
  • There is a paucity of reports of LYG in renal transplant recipients.
  • Herein, we describe LYG in a 56-year-old renal allograft recipient 11 years after transplantation, on azathioprine and prednisolone maintenance immunosuppression, presenting to us with fever, weight loss, and nodular and patchy opacities in both lung fields.
  • We have reviewed the radiological and pathological findings, and discussed clinical features, differential diagnosis, and treatment of LYG.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lung Neoplasms. Lymphomatoid Granulomatosis. Transplantation, Homologous / adverse effects


16. Kolodziejek AM, Sinclair DJ, Seo KS, Schnider DR, Deobald CF, Rohde HN, Viall AK, Minnich SS, Hovde CJ, Minnich SA, Bohach GA: Phenotypic characterization of OmpX, an Ail homologue of Yersinia pestis KIM. Microbiology; 2007 Sep;153(Pt 9):2941-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of OmpX, an Ail homologue of Yersinia pestis KIM.
  • For Yersinia enterocolitica and Yersinia pseudotuberculosis, Ail, YadA and Inv, have been implicated in these processes.
  • Genomic analysis of two Y. pestis strains revealed four loci with sequence homology to Ail.
  • The mature protein has a predicted molecular mass of 17.47 kDa, shares approximately 70 % sequence identity with Y. enterocolitica Ail, and has an identical homologue, designated Ail, in the Y. pestis CO92 database.
  • The parental strain (and a merodiploid control strain) expressed OmpX at 28 and 37 degrees C, and the protein was detectable throughout all phases of growth.
  • These results suggest that Y. pestis OmpX shares functional homology with Y. enterocolitica Ail in adherence, internalization into epithelial cells and serum resistance.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768237.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016454; United States / NCRR NIH HHS / RR / P20 RR15587; United States / NIAID NIH HHS / AI / U54AI57141
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Proteome; EC 3.- / Hydrolases
  •  go-up   go-down


17. Kodama K, Oda K, Okami J, Maeda J, Wang L, Higashiyama M, Nakayama T: [The value of long-term postoperative follow-up after curative resection of lung cancer and common problems associated with it]. Nihon Geka Gakkai Zasshi; 2007 May;108(3):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the calculation of the costs per life-year gained (LYG) of our follow-up program, an estimated survival benefit of 226 days was used.
  • Consequently, the costs per LYG were calculated at almost 4,500,000 yen.
  • In conclusion, the costs per LYG seem to be acceptable in the light of Japanese average annual earnings.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533945.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. de la Cámara R, Jarque I, Sanz MA, Grau S, Casado MA, Sabater FJ, Carreras E: Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant; 2010 May;45(5):925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A decision-analytic model was developed to assess the average per patient treatment costs, IFIs avoided, life-years gained (LYG) and incremental cost per LYG for each prophylactic treatment used (in euros at 2007 prices).
  • Posaconazole was associated with fewer IFIs (5.3 vs 9%), increased LYG (8.01 vs 7.78) and higher IFI-related costs ([euro]11 585 vs [euro]6 959) per patient compared with fluconazole.
  • The incremental cost-effectiveness of posaconazole vs fluconazole was estimated at [euro]20 246 per LYG.
  • There was a 70% probability that posaconazole is cost-effective at a [euro]30 000 per LYG threshold.
  • [MeSH-major] Fluconazole / economics. Fluconazole / therapeutic use. Graft vs Host Disease / therapy. Mycoses / prevention & control. Triazoles / economics. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Bone Marrow Transplant. 2010 May;45(5):966
  • (PMID = 19802030.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Triazoles; 6TK1G07BHZ / posaconazole; 8VZV102JFY / Fluconazole
  •  go-up   go-down


19. Seifried C, Weidauer S, Hinsch N, Bug R, Steinmetz H: [Cerebral lymphomatoid granulomatosis. A case report]. Nervenarzt; 2007 Feb;78(2):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral lymphomatoid granulomatosis. A case report].
  • [Transliterated title] Zerebrale lymphomatoide Granulomatose. Ein Fallbericht.
  • MR imaging revealed multiple lesions, particularly in the subcortical white matter, with spot like central contrast enhancement.
  • The diagnosis of lymphomatoid granulomatosis was finally made through open lung biopsy.
  • Despite treatment with rituximab and, in the later course of the disease, additionally with cyclophosphamide, the patient died 3 months after the diagnosis was made.
  • [MeSH-major] Brain Neoplasms / complications. Confusion / etiology. Fever of Unknown Origin / etiology. Lymphomatoid Granulomatosis / complications. Magnetic Resonance Imaging. Radiography, Thoracic. Tomography, X-Ray Computed


20. Soini EJ, Davies G, Martikainen JA, Hu HX, Tunceli K, Niskanen L: Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin; 2010 Jan;26(1):25-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland.
  • OBJECTIVE: To evaluate the cost-effectiveness of generic atorvastatin 20 mg (A20), branded rosuvastatin 10 mg (R10), generic simvastatin 40 mg (S40) and the combination of generic S40 + branded ezetimibe 10 mg (S40 + EZ10) for the secondary prevention of coronary heart disease (CHD) in Finnish patients not meeting the target goal of low-density lipoprotein cholesterol (LDL-C) with S40.
  • MAIN OUTCOME MEASURES: Incremental cost per quality-adjusted life year (QALY) gained and incremental cost per life year gained (LYG).
  • [MeSH-major] Coronary Disease / prevention & control. Cost of Illness

  • Genetic Alliance. consumer health - Heart Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895364.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol, LDL
  •  go-up   go-down


21. Nishihara H, Tateishi U, Itoh T, Nagashima K, Tanaka S: Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis. Neuropathology; 2007 Oct;27(5):413-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis.
  • Lymphomatoid granulomatosis (LYG) is a rare multisystem disorder with characteristic angiocentric lymphoproliferative features, most frequently involving the lung, skin, and rarely the CNS.
  • LYG has been classified into three subtypes based on the relative proportions of atypical and inflammatory infiltrating cells.
  • Most systemic LYGs have been shown to be EBV-associated, T-cell rich, B-cell proliferative disorders.
  • Here, we present four cases of LYG arising from the CNS and have analyzed them by immunohistochemistry to assess the phenotype of the infiltrate, and by PCR-SSCP (single-strand conformation polymorphism) analysis for immunoglobulin heavy chain (IgH) and T-cell receptor (TcR) gamma gene rearrangements.
  • Three cases revealed perivascular infiltration of T-cell dominant lymphoid cells, two cases showed monoclonal TcRgamma gene rearrangement, while the remaining case had a B-cell immunophenotype and monoclonal IgH gene rearrangement with EBV genome expression.
  • This is the first report of a gene rearrangement study on CNS-LYG.
  • We confirm that some cases of CNS-LYG are derived from T-cell monoclonal lymphoproliferative disease, although this disease should be classified as a borderline malignancy and should be separated from overt malignant lymphoma of CNS.
  • [MeSH-major] Central Nervous System Diseases / pathology. Gene Rearrangement. Genes, T-Cell Receptor gamma. Immunoglobulin Heavy Chains / genetics. Lymphomatoid Granulomatosis / pathology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018473.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


22. Martín-Jiménez M, Rodríguez-Lescure A, Ruiz-Borrego M, Seguí-Palmer MA, Brosa-Riestra M: Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol; 2009 Jan;11(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results are shown as cost per life year gained (C/LYG) and cost per quality-adjusted life year (C/QALY).
  • The results of the cost-effectiveness analysis showed that TAC achieves a C/LYG and a C/QALY of only euro2345 and euro2631, respectively.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2713-25 [12039934.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1205-12 [16766587.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2302-13 [15930421.001]
  • [Cites] Oncologist. 2003;8(3):232-40 [12773745.001]
  • [Cites] Pharmacoeconomics. 1997 May;11(5):492-7 [10168037.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):215-22 [12509954.001]
  • [Cites] Value Health. 2004 Jan-Feb;7(1):70-8 [14720132.001]
  • [Cites] Gac Sanit. 2002 Jul-Aug;16(4):334-43 [12113733.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):152-9 [9107610.001]
  • [Cites] Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S11-5 [9435927.001]
  • [Cites] Pharmacoeconomics. 1996 Nov;10(5):504-21 [10169397.001]
  • [Cites] Med Decis Making. 1983;3(4):419-458 [6668990.001]
  • [Cites] N Engl J Med. 2003 Nov 6;349(19):1793-802 [14551341.001]
  • [Cites] Pharmacoeconomics. 1998 Apr;13(4):397-409 [10178664.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2738-46 [8874335.001]
  • (PMID = 19155203.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther; 2006 Mar;28(3):432-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
  • OBJECTIVE: This study estimated the cost-effectiveness,from the Dutch health care perspective, of screening for albuminuria in the general Dutch population to prevent cardiovascular events (CVEs) with subsequent angiotensin-converting enzyme inhibitor treatment, using data from the Prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND IT).
  • METHODS: PREVEND IT was a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design within the larger observational Prevention of REnal and Vascular ENdstage Disease (PREVEND) study.
  • Cost-effectiveness estimates for the Dutch population were expressed in euros (2002; 1 euro = US 1.01 dollars) as net costs per life-year gained (LYG) in the baseline and sensitivity (stochastic) analyses.
  • The cost-effectiveness of screening for albumnuria was determined to be euro 16,700/LYG for the study population.
  • Stochastic analysis indicated that the probability of the cost-effectiveness being below the suggested Dutch threshold of euro 20,000/LYG was 59% in the baseline analysis.
  • The probability of cost-effectiveness below euro 20,000/LYG would increase to 91% if only subjects with UAE >50 mg/d were treated with fosinopril.


24. Peirce JL, Broman KW, Lu L, Chesler EJ, Zhou G, Airey DC, Birmingham AE, Williams RW: Genome Reshuffling for Advanced Intercross Permutation (GRAIP): simulation and permutation for advanced intercross population analysis. PLoS One; 2008 Apr 23;3(4):e1977
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Advanced intercross lines (AIL) are segregating populations created using a multi-generation breeding protocol for fine mapping complex trait loci (QTL) in mice and other organisms.
  • Applying QTL mapping methods for intercross and backcross populations, often followed by naïve permutation of individuals and phenotypes, does not account for the effect of AIL family structure in which final generations have been expanded and leads to inappropriately low significance thresholds.
  • The critical problem with naïve mapping approaches in AIL populations is that the individual is not an exchangeable unit.
  • METHODOLOGY/PRINCIPAL FINDINGS: The effect of family structure has immediate implications for the optimal AIL creation (many crosses, few animals per cross, and population expansion before the final generation) and we discuss these and the utility of AIL populations for QTL fine mapping.
  • We also describe Genome Reshuffling for Advanced Intercross Permutation, (GRAIP) a method for analyzing AIL data that accounts for family structure.
  • GRAIP permutes a more interchangeable unit in the final generation crosses - the parental genome - and simulating regeneration of a permuted AIL population based on exchanged parental identities.
  • GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures.
  • We contrast GRAIP with naïve permutation using a large densely genotyped mouse AIL population (1333 individuals from 32 crosses).
  • GRAIP also detects an established hippocampus weight locus and a new locus, Hipp9a.
  • CONCLUSIONS AND SIGNIFICANCE: GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures.
  • The effect of family structure has immediate implications for the optimal AIL creation and we discuss these and the utility of AIL populations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mamm Genome. 2000 Aug;11(8):645-8 [10920233.001]
  • [Cites] PLoS One. 2007;2(10):e1036 [17940600.001]
  • [Cites] J Neurosci. 2001 May 15;21(10):3503-14 [11331379.001]
  • [Cites] Genomics. 2001 May 15;74(1):89-104 [11374905.001]
  • [Cites] Genetics. 2001 Sep;159(1):371-87 [11560912.001]
  • [Cites] Hum Hered. 2001;52(3):121-31 [11588394.001]
  • [Cites] Genome Biol. 2001;2(11):RESEARCH0046 [11737945.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):920-34 [11880950.001]
  • [Cites] Genetics. 2002 Mar;160(3):1123-31 [11901128.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):235-6 [12089518.001]
  • [Cites] Neuropsychopharmacology. 2003 Apr;28(4):818; author reply 819 [12655329.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3317-24 [12810665.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1654-64 [12805272.001]
  • [Cites] Genes Brain Behav. 2003 Aug;2(4):238-52 [12953790.001]
  • [Cites] Nat Rev Genet. 2003 Nov;4(11):911-6 [14634638.001]
  • [Cites] Neuroinformatics. 2003;1(4):343-57 [15043220.001]
  • [Cites] BMC Genet. 2004 Apr 29;5:7 [15117419.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1366-73 [15240732.001]
  • [Cites] Mamm Genome. 2004 Aug;15(8):637-47 [15457343.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1133-7 [15514660.001]
  • [Cites] J Dairy Sci. 1990 Sep;73(9):2525-37 [2258496.001]
  • [Cites] Genetics. 1994 Nov;138(3):963-71 [7851788.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1323-37 [8651310.001]
  • [Cites] Mamm Genome. 1999 Apr;10(4):335-48 [10087289.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Apr;40(5):817-25 [10102277.001]
  • [Cites] Genetics. 2005 Feb;169(2):1133-46 [15545647.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):233-42 [15711545.001]
  • [Cites] Genetics. 2005 May;170(1):283-9 [15716504.001]
  • [Cites] Genetics. 2005 Jul;170(3):1299-311 [15879512.001]
  • [Cites] Mamm Genome. 2005 May;16(5):344-55 [16104382.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):641-9 [11195461.001]
  • (PMID = 18431467.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / U01AA01442501; United States / NIMH NIH HHS / MH / P20 MH062009; United States / NHLBI NIH HHS / HV / HV48141; United States / NIAAA NIH HHS / AA / U01 AA013499; United States / NIAAA NIH HHS / AA / U01AA13499; United States / NIAAA NIH HHS / AA / U24AA135B; United States / NIMH NIH HHS / MH / P20-MH62009; United States / NHLBI NIH HHS / HL / N01HV48141
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2295257
  •  go-up   go-down


25. Fidan D, Unal B, Critchley J, Capewell S: Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. QJM; 2007 May;100(5):277-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
  • BACKGROUND: Coronary heart disease (CHD) in the UK affects approximately 3 million people, with >100,000 deaths annually.
  • METHODS: The IMPACT CHD model was used to calculate the number of life-years gained (LYG) from specific cardiological interventions from 2000 to 2010.
  • Cost-effectiveness ratios (costs per LYG) were generated for each specific intervention, stratified by age and sex.
  • Aspirin and beta-blockers for secondary prevention following myocardial infarction or revascularisation, for angina and heart failure were highly cost-effective (< 1000 pounds per LYG).
  • Other secondary prevention therapies, including cardiac rehabilitation, ACE inhibitors and statins, were reasonably cost-effective (1957 pounds, 3398 pounds and 4246 pounds per LYG, respectively), as were CABG surgery (3239 pounds-4601 pounds per LYG) and angioplasty (3845 pounds-5889 pounds per LYG).
  • Primary angioplasty for myocardial infarction was intermediate (6054 pounds-12,057 pounds per LYG, according to age), and statins in primary prevention were much less cost-effective (27,828 pounds per LYG, reaching 69,373 pounds per LYG in men aged 35-44).
  • [MeSH-major] Coronary Disease / economics. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449875.001).
  • [ISSN] 1460-2725
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Fibrinolytic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


26. Halvani A, Owlia MB, Sami R: Lymphomatoid granulomatosis with splenomegaly and pancytopenia. Zhongguo Fei Ai Za Zhi; 2010 Jan;13(1):84-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis with splenomegaly and pancytopenia.
  • Lymphomatoid granulomatosis (LG) is an angiocentric lymphoproliferative disease.
  • It usually involves lung, skin, and central nervous system, but splenomegaly and pancytopenia are the rare manifestations of the disease.
  • We report a 15-year-old boy presented with fever, dry cough and dyspnea from two months ago, after admission patient had nodular lesions on the left leg and hepatosplenomegaly.
  • Skin biopsy was done, and histopathological examination and immunohistochemistry evaluation confirmed lymphomatoid granulomatosis.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis. Pancytopenia / diagnosis. Splenomegaly / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672711.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Pal I, Gupta A, Sengupta S: An attempt to define the type of biopsy in a sinonasal lesion showing bony erosion. Indian J Otolaryngol Head Neck Surg; 2010 Jan;62(1):92-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An attempt to define the type of biopsy in a sinonasal lesion showing bony erosion.
  • OBJECTIVES: To present a case of sino-nasal destructive mass initially diagnosed as an inflammatory lesion following punch biopsy from the lesion however the post surgical histopathology was diagnostic of Grade 2 angiocentric immunoproliferative lesion (AIL).
  • Repeated punch biopsies from the mass were suggestive of an inflammatory lesion.
  • RESULT: The patient underwent surgical exenteration of the mass and the final histopathology report suggested AIL Grade 2.
  • CONCLUSION: Initial superficial punch biopsies lead to incorrect diagnosis leading to an unnecessary surgical exenteration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1995 Oct;48(10):946-9 [8537496.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):255-63 [11904341.001]
  • [Cites] Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):73-6 [17992462.001]
  • (PMID = 23120692.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450158
  • [Keywords] NOTNLM ; Angiocentric immunoproliferative lesion / Angiocentricity / Incisional biopsy
  •  go-up   go-down


28. Best medicines for less: we compare drugs for what ails America. Consum Rep; 2008 Jan;73(1):27-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best medicines for less: we compare drugs for what ails America.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18488284.001).
  • [ISSN] 0010-7174
  • [Journal-full-title] Consumer reports
  • [ISO-abbreviation] Consum Rep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Generic
  •  go-up   go-down


29. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • Patients who are transplanted in a refractory disease state do not benefit from this procedure.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Registries. Severity of Illness Index. Spain. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. Rogers DG, Aliano VA: Metastatic angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat. J Vet Diagn Invest; 2009 May;21(3):390-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat.
  • A subcutaneous mass removed from the right rear leg of a 17-year-old, spayed, female Domestic Shorthair cat was characterized histopathologically by granulomatous inflammation, sheets of large atypical lymphoid cells, and necrosis.
  • The walls of the small and medium caliber blood vessels were invaded transmurally by atypical lymphoid cells.
  • A diagnosis of angioinvasive lymphoma (AIL), or lymphomatoid granulomatosis, was made based on histopathologic findings.
  • The cat was euthanized 2 months later because of recurrence of the mass and elevated serum alanine aminotransferase activity, and a necropsy was performed.
  • The histopathologic lesion of AIL was seen in the skin and subcutis of the right rear leg, and neoplastic cell infiltrates were seen in adjacent skeletal muscle, right superficial inguinal lymph node, liver, and spleen.
  • Although the cat had received a Rabies virus vaccine subcutaneously in the right rear leg 6 months earlier, the AIL lesion was not typical of vaccine-induced sarcomas.
  • The AIL in this cat was unusual because the extrapulmonary metastases involved the skin and subcutis.
  • [MeSH-major] Cat Diseases / diagnosis. Lymphomatoid Granulomatosis / veterinary. Neoplasms, Connective Tissue / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407098.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Drut R, Drut RM: Angiocentric immunoproliferative lesion and angiocentric lymphoma of lymph node in children. A report of two cases. J Clin Pathol; 2005 May;58(5):550-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiocentric immunoproliferative lesion and angiocentric lymphoma of lymph node in children. A report of two cases.
  • AIM: To report two examples of an angiocentric immunoproliferative lesion (AIL) and angiocentric angiodestructive lymphoma (AL) presenting in lymph nodes in children.
  • Most commonly involving extranodal sites, AIL/AL rarely presents in the spleen and lymph nodes.
  • Histological and immunohistochemistry studies revealed an Epstein-Barr virus positive (EBV+), large B cell (CD20 and CD30+) AIL with large areas of necrosis, the whole resembling lymphomatoid granulomatosis.
  • Histology and immunohistochemistry revealed an EBV-, large T cell (CD45RO, CD56, and CD30+) AL, presenting the features of so called angiocentric T cell/natural killer cell lymphoma, nasal type.
  • CONCLUSIONS: The term AIL/AL refers to a heterogeneous group of conditions not unique to a particular type of lymphoid cell.
  • These lesions are easily recognised by the histopathologist because of their extremely unusual angiocentric pattern.
  • Although rare, AIL/AL may present as nodal lesions in children ab initio.
  • [MeSH-major] Immunoproliferative Disorders / pathology. Lymph Nodes / pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Child, Preschool. Female. Humans. Immunohistochemistry. Lymphomatoid Granulomatosis / pathology. Male

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):93-5 [11244444.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):555-7 [12835306.001]
  • [Cites] J Neurol Sci. 2003 Sep 15;213(1-2):67-76 [12873757.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4280-3 [6272972.001]
  • [Cites] Pediatr Pathol. 1988;8(4):395-400 [3062603.001]
  • [Cites] Am J Hematol. 1989 Feb;30(2):104-11 [2913758.001]
  • [Cites] Med Pediatr Oncol. 1999 Jun;32(6):447-9 [10358706.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):439-47 [1318000.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):623-31 [8179077.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1300-12 [7573693.001]
  • [Cites] Am J Clin Pathol. 1996 Jul;106(1):69-77 [8701936.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):77-81 [9065724.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):378-84 [2155307.001]
  • (PMID = 15858132.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770650
  •  go-up   go-down


32. Street A, Hill K, Sussex B, Warner M, Scully MF: Haemophilia and ageing. Haemophilia; 2006 Jul;12 Suppl 3:8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Men with haemophilia have not only the challenges of living with HIV and/or HCV infection and premature arthritis as complications of their disorder, but they also confront the other ails of ageing.
  • These include genitourinary problems such as prostatic hypertrophy, prostatic cancer and renal stone disease, and arterial disease for which haemophilia is not protective.
  • Many older men with haemophilia may never have consulted primary care physicians because of the rarity and complexity of their disorder.
  • We need to be aware of the ageing issues in haemophilia and develop 'wellness' programs which are directed to the early identification of disease as well as preventative strategies to reduce the physical and psychological impacts of ageing.


33. Okuda T, Akai F, Kataoka K, Taneda M: A case of lymphomatoid granulomatosis followed for 14 months on the basis of clinical and histological findings. Brain Tumor Pathol; 2008;25(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphomatoid granulomatosis followed for 14 months on the basis of clinical and histological findings.
  • Lymphomatoid granulomatosis (LYG) is a systemic granulomatous disease characterized by B-cell proliferation of uncertain malignant potential.
  • We recently encountered a case of LYG that was followed clinically and histologically for 14 months.
  • A 55-year-old man was hospitalized with multiple brain tumors for which the final diagnosis was not made until the second surgery, 14 months after the first intervention.
  • Following the diagnosis, he was treated with steroid pulse therapy.
  • At present, 3.5 years after the onset of LYG, the patient is in good condition with no signs of tumor recurrence.
  • Although LYG is usually graded on the basis of histological findings, this patient showed no histological changes or any increase in disease grade during the 14-month follow-up period.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphomatoid Granulomatosis / pathology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415664.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


34. Furuta K, Nakagawa A, Morita K, Tajiri T, Nishiyama H, Nohgawa M, Ono K, Kobashi Y: [A case of lymphomatoid granulomatosis which initially demonstrated a diffuse ground glass appearance]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lymphomatoid granulomatosis which initially demonstrated a diffuse ground glass appearance].
  • Lymphomatoid granulomatosis is defined as an Epstein-Barr virus-associated B-cell lymphoma which possibly progresses to malignant lymphoma.
  • The pulmonary lesions associated with this disease typically reveal multiple poorly defined nodules.
  • We finally diagnosed lymphomatoid granulomatosis (grade 2) based on the findings of a thoracoscopic lung biopsy.
  • Pathologically, an angiocentric proliferation of large atypical lymphoid cells were observed which were positive for EBER (EBV-encoded small RNA).
  • [MeSH-major] Lung / radiography. Lung Neoplasms / radiography. Lymphomatoid Granulomatosis / radiography

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163022.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D: Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol; 2009 Feb;64(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
  • The aim of this study is to determine the cost-effectiveness of statins for the primary prevention of cardiovascular disease (CVD) in middle-aged Belgian populations.
  • Prescribing the cheapest statin on the Belgian market (< Euro 90 medication cost per year) resulted in an incremental cost of Euro 29,173 per life-year gained (LYG) in a male high-risk group aged 60 compared to low-dose aspirin.
  • The incremental cost in a male moderate-risk group aged 50 was Euro 87,022/LYG.
  • Low-dose aspirin was more cost-effective ranging from Euro 3,854/LYG to Euro 29,509/LYG compared to smoking cessation therapy.

  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317290.001).
  • [ISSN] 0001-5385
  • [Journal-full-title] Acta cardiologica
  • [ISO-abbreviation] Acta Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  • [Number-of-references] 27
  •  go-up   go-down


36. Divgi C: Editorial: what ails solid tumor radioimmunotherapy? Cancer Biother Radiopharm; 2006 Apr;21(2):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial: what ails solid tumor radioimmunotherapy?

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706627.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab; P188ANX8CK / Trastuzumab
  •  go-up   go-down


37. Simons J: A new CEO'S RX for what ails Merck. Fortune; 2005 May 30;151(11):28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new CEO'S RX for what ails Merck.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15926519.001).
  • [ISSN] 0015-8259
  • [Journal-full-title] Fortune
  • [ISO-abbreviation] Fortune
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


38. Patsalides AD, Atac G, Hedge U, Janik J, Grant N, Jaffe ES, Dwyer A, Patronas NJ, Wilson WH: Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology; 2005 Oct;237(1):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging.
  • PURPOSE: To retrospectively evaluate the magnetic resonance (MR) imaging features of lymphomatoid granulomatosis in the brain.
  • Thirty-one patients with pathologically confirmed lymphomatoid granulomatosis were enrolled in a natural history and treatment study at the National Institutes of Health.
  • Twenty-five patients (median age, 50 years; range, 18-62 years; 18 men, seven women) were evaluated with MR imaging of the brain at study entry for the presence of brain lesions and enhancing characteristics.
  • Multiple focal intraparenchymal lesions, which exhibited T2 prolongation and commonly punctate or linear enhancement, were the most frequent abnormalities, and they were encountered in seven patients.
  • The second most common finding was involvement of leptomeninges and cranial nerves, which manifested as abnormal enhancement on MR images obtained after contrast agent administration.
  • This abnormality was seen in six patients.
  • Most lesions resolved after treatment, but seven resulted in lacunar infarctions.
  • CONCLUSION: Lymphomatoid granulomatosis has a high rate of central nervous system involvement and a variable spectrum of lesions at MR imaging.
  • Findings in this study suggest that MR imaging is more sensitive than CSF cytologic analysis or flow cytometry for detection of central nervous system involvement from lymphomatoid granulomatosis.
  • [MeSH-major] Brain / pathology. Lymphomatoid Granulomatosis / pathology. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005
  • (PMID = 16100084.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Wu SM, Min Y, Ostrzega N, Clements PJ, Wong AL: Lymphomatoid granulomatosis: a rare mimicker of vasculitis. J Rheumatol; 2005 Nov;32(11):2242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: a rare mimicker of vasculitis.
  • Lymphomatoid granulomatosis (LG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder, with a propensity for blood vessel destruction.
  • Since LG often mimics systemic vasculitis, it presents a diagnostic clinical challenge.
  • We describe a case of LG with no pulmonary involvement, which was thought to be systemic vasculitis on the basis of multiorgan involvement and biopsy findings.
  • [MeSH-major] Lymphoma / pathology. Lymphomatoid Granulomatosis / pathology. Vasculitis / pathology
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Tomography, X-Ray Computed


40. Bucher M, Meyer C, Grötzbach B, Wacheck S, Stolle A, Fredriksson-Ahomaa M: Epidemiological data on pathogenic Yersinia enterocolitica in Southern Germany during 2000-2006. Foodborne Pathog Dis; 2008 Jun;5(3):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No pathogenic strains were isolated from cattle, sheep, turkey, and horses. ail-Positive Y. enterocolitica was detected in dogs (5%), cats (3%), and rodents (3%) by real-time PCR.

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564908.001).
  • [ISSN] 1556-7125
  • [Journal-full-title] Foodborne pathogens and disease
  • [ISO-abbreviation] Foodborne Pathog. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


41. Gupta T, Wadasadawala T, Shet T, Jalali R, Menon H: Isolated central nervous system involvement by lymphomatoid granulomatosis in an adolescent: a case report and review of literature. Pediatr Hematol Oncol; 2010 Mar;27(2):150-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system involvement by lymphomatoid granulomatosis in an adolescent: a case report and review of literature.
  • Lymphomatoid granulomatosis is an Epstein-Barr virus-associated multisystem disease that combines granulomatous inflammatory process with lymphoproliferative potential.
  • It predominantly affects lungs, skin, and brain and is characterized by multifocal, transmural, angiocentric, and angiodestructive pleomorphic lymphoid infiltrate in a perivascular distribution.
  • Lymphomatoid granulomatosis is generally considered to be a neoplastic B-cell proliferation that has traditionally been associated with poor prognosis, evolving as a progressive multisystem disease transforming into B-cell lymphoma, with a median survival of 14 to 16 months only.
  • Neuroimaging showed 2 space-occupying lesions, larger in the left frontoparietal region with heterogeneous enhancement, moderate perifocal edema, compression, and mass effect.
  • He underwent surgical decompression of the dominant lesion with prompt relief of symptoms.
  • The diagnosis of lymphomatoid granulomatosis was confirmed on light microscopy and immunohistochemistry.
  • Awareness of disease spectrum in the central nervous system may permit early diagnosis and thus allow institution of timely appropriate therapy.
  • [MeSH-major] Central Nervous System / pathology. Central Nervous System / physiopathology. Lymphomatoid Granulomatosis / complications

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201696.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


42. Bhagat N, Virdi JS: Distribution of virulence-associated genes in Yersinia enterocolitica biovar 1A correlates with clonal groups and not the source of isolation. FEMS Microbiol Lett; 2007 Jan;266(2):177-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Virulence-associated genes viz. ail, virF, inv, myfA, ystA, ystB, ystC, tccC, hreP, fepA, fepD, fes, ymoA and sat were studied in 81 clinical and nonclinical strains of Y. enterocolitica biovar 1A by PCR amplification.
  • All strains lacked ail, virF, ystA and ystC genes.
  • The clonal groups A and B were differentiated previously based on rep (REP-/ERIC) - PCR genomic fingerprinting.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233728.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY966878/ AY966879/ AY966880/ AY966881/ AY970513/ AY970514/ AY970515/ AY970518/ AY970519/ DQ144904/ DQ144905/ DQ144908/ DQ144909/ DQ144910/ DQ144911
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Kwon EJ, Katz KA, Draft KS, Seykora JT, Rook AH, Wasik MA, Junkins-Hopkins JM: Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient. J Am Acad Dermatol; 2006 Apr;54(4):657-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient.
  • A skin biopsy specimen revealed a dense angiocentric and angioinvasive infiltrate in the mid to reticular dermis and panniculus containing large, atypical lymphocytes with convoluted nuclei and prominent nucleoli.
  • The clinical and pathologic features in this case represent posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis.
  • The case also highlights the importance of clinical and pathologic examination of cutaneous lesions in the evaluation of lymphoproliferative disorders for patients undergoing transplantation.
  • [MeSH-major] Lung Diseases / pathology. Lung Transplantation / adverse effects. Lymphomatoid Granulomatosis / pathology. Lymphoproliferative Disorders / pathology. Skin Diseases / pathology


44. Anel L, Kaabi M, Abroug B, Alvarez M, Anel E, Boixo JC, de la Fuente LF, de Paz P: Factors influencing the success of vaginal and laparoscopic artificial insemination in churra ewes: a field assay. Theriogenology; 2005 Mar 1;63(4):1235-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work we studied the influence of many factors on the fertility of the Churra breed (insemination technique, year, farm, age, male, number of inseminations per ewe, lambing-insemination interval and technician), analyzing lambing data obtained after 44448 inseminations (39.67% cervical AI via vagina, AIV, and 60.33% intrauterine AI using laparoscopy, AIL) in a categorical model.
  • AIL showed significantly higher fertility results than AIV (44.89% versus 31.25%).
  • Fertility dropped 1.74% (AIV) and 2.07% (AIL) per year as the ewes aged.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710206.001).
  • [ISSN] 0093-691X
  • [Journal-full-title] Theriogenology
  • [ISO-abbreviation] Theriogenology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Tavazzi E, Bargiggia V, Pichiecchio A, Delbue S, Maserati R, Bastianello S, Ferrante P, Minoli L, Ricevuti G, Ceroni M, Marchioni E: HIV-related acute inflammatory leukoencephalopathy of undetermined origin: review of the literature. Int J Immunopathol Pharmacol; 2010 Jul-Sep;23(3):693-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-related acute inflammatory leukoencephalopathy of undetermined origin (AIL) has been anecdotally described in literature as being responsible for cognitive and motor deficits.
  • We carried out a review of all the cases of AIL published in literature.
  • Although rare (21 patients out of about 4,000 publications), AIL is of particular interest, as the comprehension of its mechanisms could give some insight into the direct and immune-mediated actions of HIV within the brain.
  • [MeSH-minor] AIDS Dementia Complex / pathology. Acute Disease. Anti-HIV Agents / therapeutic use. Brain / pathology. HIV Seropositivity. Humans. Magnetic Resonance Imaging. Spinal Cord / pathology. Terminology as Topic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943038.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Editorial; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


46. Rho JH, Roehrl MH, Wang JY: Glycoproteomic analysis of human lung adenocarcinomas using glycoarrays and tandem mass spectrometry: differential expression and glycosylation patterns of vimentin and fetuin A isoforms. Protein J; 2009 May;28(3-4):148-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advances in pathophysiologic understanding and novel biomarkers for diagnosis and treatment are significant tasks.
  • Glycoproteins from paired lung adenocarcinoma and normal tissues were enriched by the lectins Con A, WGA, and AIL.
  • WGA- and AIL-binding glycosylated fetuin A was also consistently decreased in cancer.
  • In particular, the discovery of differentially glycosylated protein isoforms in lung adenocarcinoma may represent avenues towards new functional biomarkers for diagnosis, treatment guidance, and response monitoring.


47. Hubben GA, Bos JM, Veltman-Starkenburg CA, Stegmeijer S, Finnern HW, Kappelhoff BS, Simpson KN, Tramarin A, Postma MJ: Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Eff Resour Alloc; 2007;5:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The model uses 12 health states based on viral load and CD4+ count to simulate disease progression.
  • This translates into an incremental effect of TPV/r over CPI/r of 0.52 life years gained (LYG) or 0.51 QALYs gained.
  • The corresponding incremental cost effectiveness ratios (iCERs) are euro41,600 per LYG and euro42,500 per QALY.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2000 Sep;182(3):758-65 [10950769.001]
  • [Cites] Pharmacoeconomics. 2000 Aug;18(2):149-60 [11067649.001]
  • [Cites] Pharmacoeconomics. 2001 Jan;19(1):95-104 [11252549.001]
  • [Cites] AIDS. 2001 Jun 15;15(9):1133-42 [11416715.001]
  • [Cites] HIV Med. 2001 Jan;2(1):52-8 [11737376.001]
  • [Cites] AIDS. 2002 Mar 29;16(5):737-45 [11964530.001]
  • [Cites] JAMA. 2002 Jul 10;288(2):181-8 [12095382.001]
  • [Cites] AIDS. 2003 Apr;17 Suppl 1:S4-11 [12870525.001]
  • [Cites] Drugs. 2003;63(15):1611-8 [12887268.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1571-7 [15238775.001]
  • [Cites] Pharmacoeconomics. 2000 Oct;18(4):393-404 [15344307.001]
  • [Cites] HIV Clin Trials. 2004 Sep-Oct;5(5):294-304 [15562370.001]
  • [Cites] Drugs. 2005;65(12):1669-77; discussion 1678-9 [16060700.001]
  • [Cites] Lancet. 2006 Aug 5;368(9534):466-75 [16890833.001]
  • [Cites] Clin Infect Dis. 2006 Nov 15;43(10):1337-46 [17051503.001]
  • [Cites] Clin Infect Dis. 2006 Nov 15;43(10):1347-56 [17051504.001]
  • [Cites] Stat Med. 2008 Mar 15;27(6):781-94 [17597471.001]
  • [Cites] Med Care. 1997 Nov;35(11):1095-108 [9366889.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1725-30 [9848347.001]
  • (PMID = 18034881.001).
  • [ISSN] 1478-7547
  • [Journal-full-title] Cost effectiveness and resource allocation : C/E
  • [ISO-abbreviation] Cost Eff Resour Alloc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211743
  •  go-up   go-down


48. Ma HL, Jin WJ, Xi L, Dong ZJ: Investigation on solvation and protonation of meso-tetrakis(p-sulfonatophenyl)porphyrin in imidazolium-based ionic liquids by spectroscopic methods. Spectrochim Acta A Mol Biomol Spectrosc; 2009 Oct 1;74(2):502-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Next, the protonation of TPPS in aprotonic ionic liquids (AILs, i.e., [MBIM]BF(4)) is dependent not only on the concentration of protonic ionic liquids as proton sources, but also on the characteristic of anion and viscosity of PILs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648056.001).
  • [ISSN] 1873-3557
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Ionic Liquids; 0 / Porphyrins; 0 / Protons; 0 / Solvents
  •  go-up   go-down


49. Lamotte M, Annemans L, Kawalec P, Zoellners Y: A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction. Herz; 2006 Dec;31 Suppl 3:74-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Life expectancy data for survivors of cardiac disease were taken from the Saskatchewan database and then country-adjusted.
  • Results are expressed as extra cost (Euro) per life-year gained (LYG).
  • Treatment with highly concentrated n-3 PUFAs yielded between 0.260 (Poland) and 0.284 (Australia) LYG, at an additional cost of Euro 807 (Canada) to Euro 1,451 (Belgium).
  • The incremental cost-effectiveness ratio (ICER) varied between Euro 2,867 (Canada) and Euro 5,154 (Belgium) per LYG.
  • A 2nd order Monte Carlo simulation based on the 95% CIs obtained from GISSI showed that highly concentrated n-3 PUFAs are cost-effective in more than 99% of patients (assuming societal willingness to pay threshold of Euro 20,000/LYG).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575809.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3
  •  go-up   go-down


50. Clark TJ, Barton PM, Coomarasamy A, Gupta JK, Khan KS: Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG; 2006 May;113(5):502-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: The cost per additional life year gained (pound/LYG) was determined and compared for each diagnostic strategy, and sensitivity analyses were performed.
  • RESULTS: Compared with carrying out no initial investigation, a strategy based on initial diagnosis with USS using a 5-mm cutoff was the least expensive (11,470 pound/LYG).
  • Initial investigation with EB or USS using a 4-mm cutoff was comparably cost-effective (less than 30,000 pound/LYG versus USS with a 5-mm cutoff) at their most favourable diagnostic performance and at disease prevalence of 10% or more.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Postmenopause. Uterine Hemorrhage / etiology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637894.001).
  • [ISSN] 1470-0328
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Pullarkat VA, Medeiros LJ, Brynes RK: Body cavity-based presentation of natural killer cell lymphoma. Leuk Lymphoma; 2005 Feb;46(2):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extranodal NK/T-cell lymphoma of nasal type is the current designation for these neoplasms in the recently proposed World Health Organization classification of lymphoid neoplasms.
  • These tumors previously have been referred to many other names, including lethal midline granuloma, midline malignant reticulosis, polymorphic reticulosis, angiocentric immunoproliferative lesion, and angiocentric lymphoma.
  • The malignant cytologic features and the presence of azurophilic granules within the cell cytoplasm observed in Wright-Giemsa-stained cytocentrifuge preparations led to immunophenotypic and molecular genetic studies that were essential in establishing the correct diagnosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / diagnosis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Herpesvirus 4, Human / isolation & purification. Humans. Pleural Cavity / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621817.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Pernthaner A, Shaw RJ, McNeill MM, Morrison L, Hein WR: Total and nematode-specific IgE responses in intestinal lymph of genetically resistant and susceptible sheep during infection with Trichostrongylus colubriformis. Vet Immunol Immunopathol; 2005 Mar 10;104(1-2):69-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total and antigen-specific IgE responses in afferent (AIL) and efferent (EIL) intestinal lymph of sheep with a nematode resistant (R) or susceptible (S) genotype during challenge infection with the intestinal nematode parasite Trichostrongylus colubriformis were examined.
  • Total IgE level in AIL and EIL was dependent on nematode infection and was further influenced by genotype or the immune phenotype (nematode immune mean FEC+/-SDM=77+/-179 or non-immune mean FEC+/-SDM=4016+/-4318) of the animal.
  • Concentrations of total IgE were consistently higher in AIL than EIL or serum and were higher in lymph draining the proximal than the distal jejunum demonstrating that polyclonal IgE in AIL was largely derived from the intestinal mucosa of the anatomical compartment where the nematodes reside.
  • The consistently higher concentration of total IgE in AIL was dependent on phenotype or genotype and in S genotype sheep also on the pre-challenge status.
  • Concentrations of nematode specific IgE were significantly higher in EIL than AIL indicating a preference for the production of IgE reacting with excretory secretory products of the infective T. colubriformis larvae in the regional lymph node.
  • [MeSH-minor] Animals. Antibodies, Helminth / analysis. Antibodies, Helminth / immunology. Antibody Specificity. Blotting, Western / veterinary. Enzyme-Linked Immunosorbent Assay / veterinary. Feces / parasitology. Female. Genetic Predisposition to Disease. Lymph / immunology. Lymph / parasitology. Male. Parasite Egg Count / veterinary. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661332.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


53. Connolly M, Bhatt A, Wechowski J, Colle I: An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. Acta Gastroenterol Belg; 2008 Apr-Jun;71(2):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed average disaggregated and aggregated treatment costs, average and incremental cost per quality adjusted life years (QALYs) and life-years gained (LYG).
  • In the cost per LYG analysis terlipressin achieved the lowest cost per life-year.
  • Results from the incremental cost per QALY and LYG analysis indicated that terlipressin was the most cost-effective agent.

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720934.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents
  •  go-up   go-down


54. DI Nisio M, Otten HM, Piccioli A, Lensing AW, Prandoni P, Büller HR, Prins MH: Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost; 2005 Nov;3(11):2391-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the tumor type, stage, age and gender of the individual cancer patient, the difference in live years gained (LYG) was calculated between the two study groups.
  • Furthermore, the strategies which included colonoscopy, tumor markers, and abdominal/pelvic US were significantly more costly, had inferior LYG and higher costs per LYG, when compared with strategies using abdominal/pelvic CT.
  • [MeSH-major] Decision Support Techniques. Mass Screening / economics. Neoplasms / diagnosis. Thromboembolism / etiology. Venous Thrombosis / etiology
  • [MeSH-minor] Cost-Benefit Analysis. Costs and Cost Analysis. Early Diagnosis. False Positive Reactions. Follow-Up Studies. Humans. Life Expectancy. Mammography / economics. Radiography, Abdominal / economics. Randomized Controlled Trials as Topic. Sputum / cytology. Tomography, X-Ray Computed / economics


55. Fälker S, Schilling J, Schmidt MA, Heusipp G: Overproduction of DNA adenine methyltransferase alters motility, invasion, and the lipopolysaccharide O-antigen composition of Yersinia enterocolitica. Infect Immun; 2007 Oct;75(10):4990-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that the increased invasion is not due to enhanced expression of known and putative Y. enterocolitica invasion and adhesion factors, such as Inv, YadA, Ail, Myf fibrils, Pil, or Flp pili.

  • REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 10380 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Microbiol. 2002 Aug;45(3):673-95 [12139615.001]
  • [Cites] PLoS Genet. 2006 Dec 15;2(12):e206 [17173484.001]
  • [Cites] Mol Microbiol. 2003 Apr;48(2):443-52 [12675803.001]
  • [Cites] Microbiology. 2003 Aug;149(Pt 8):2283-90 [12904568.001]
  • [Cites] J Bacteriol. 2003 Sep;185(17):5096-108 [12923082.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):738-44 [7836309.001]
  • [Cites] Infect Immun. 1995 Oct;63(10):4199-201 [7558344.001]
  • [Cites] J Med Microbiol. 1996 Apr;44(4):285-94 [8606357.001]
  • [Cites] Gene. 1996 Dec 12;183(1-2):207-13 [8996108.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):257-76 [9105754.001]
  • [Cites] J Bacteriol. 1998 Feb;180(4):793-800 [9473031.001]
  • [Cites] FEMS Microbiol Rev. 2003 Oct;27(4):505-23 [14550943.001]
  • [Cites] Mol Microbiol. 2004 Apr;52(2):451-69 [15066033.001]
  • [Cites] Trends Microbiol. 2004 Jun;12(6):296-300 [15165608.001]
  • [Cites] Mol Microbiol. 2004 Jul;53(2):651-64 [15228541.001]
  • [Cites] Infect Immun. 2004 Aug;72(8):4784-90 [15271940.001]
  • [Cites] Anal Biochem. 1982 Jan 1;119(1):115-9 [6176137.001]
  • [Cites] Gene. 1984 Apr;28(1):123-5 [6376282.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] J Bacteriol. 1988 Jun;170(6):2575-83 [2836362.001]
  • [Cites] J Bacteriol. 1988 Jul;170(7):3213-6 [3384807.001]
  • [Cites] N Engl J Med. 1989 Jul 6;321(1):16-24 [2659991.001]
  • [Cites] Gut. 1990 Sep;31(9):1011-5 [2210445.001]
  • [Cites] Nature. 1992 Dec 10;360(6404):606-10 [1334233.001]
  • [Cites] Mol Microbiol. 1993 Aug;9(3):507-20 [8105362.001]
  • [Cites] Gene. 1993 Dec 22;136(1-2):271-5 [8294016.001]
  • [Cites] J Bacteriol. 1994 Jul;176(13):4043-51 [8021186.001]
  • [Cites] Infect Immun. 2000 Jul;68(7):4323-6 [10858252.001]
  • [Cites] J Bacteriol. 2000 Oct;182(19):5563-71 [10986262.001]
  • [Cites] Microbiol Mol Biol Rev. 2000 Dec;64(4):694-708 [11104815.001]
  • [Cites] Int J Med Microbiol. 2001 Aug;291(3):209-18 [11554561.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7610-5 [11705940.001]
  • [Cites] J Bacteriol. 2002 Feb;184(3):645-53 [11790733.001]
  • [Cites] Infect Immun. 2002 Feb;70(2):1006-9 [11796641.001]
  • [Cites] Mol Microbiol. 2002 May;44(4):1045-62 [12010497.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] J Bacteriol. 1999 May;181(9):2823-33 [10217774.001]
  • [Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11578-83 [10500219.001]
  • [Cites] Nat Rev Microbiol. 2005 Jan;3(1):36-46 [15608698.001]
  • [Cites] FEMS Microbiol Lett. 2005 Apr 1;245(1):53-9 [15796979.001]
  • [Cites] Microbiology. 2005 Jun;151(Pt 6):1919-26 [15941999.001]
  • [Cites] Microbiology. 2005 Jul;151(Pt 7):2291-9 [16000719.001]
  • [Cites] Cell Microbiol. 2005 Oct;7(10):1474-89 [16153246.001]
  • [Cites] FEMS Microbiol Lett. 2005 Nov 15;252(2):251-6 [16188402.001]
  • [Cites] Infect Immun. 2006 Jan;74(1):410-24 [16368997.001]
  • [Cites] Nat Rev Microbiol. 2006 Mar;4(3):183-92 [16489347.001]
  • [Cites] Microbiol Mol Biol Rev. 2006 Sep;70(3):830-56 [16959970.001]
  • [Cites] J Bacteriol. 2006 Oct;188(20):7072-81 [17015646.001]
  • [Cites] J Bacteriol. 2006 Dec;188(23):8160-8 [16997949.001]
  • [Cites] Infect Immun. 2006 Dec;74(12):6675-81 [16982842.001]
  • [Cites] Int J Med Microbiol. 2007 Feb;297(1):1-7 [17126598.001]
  • [Cites] J Bacteriol. 2007 Mar;189(5):1556-64 [17172341.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1512-6 [17178779.001]
  • [Cites] FEMS Microbiol Lett. 2007 Mar;268(2):187-93 [17328745.001]
  • [Cites] Nat Rev Microbiol. 2007 May;5(5):363-75 [17435791.001]
  • [Cites] Infect Immun. 2002 Nov;70(11):6196-205 [12379698.001]
  • (PMID = 17682042.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Bacterial Proteins; 0 / DNA, Bacterial; 0 / O Antigens; 114073-91-5 / invasin, Yersinia; EC 2.1.1.72 / Dam methyltransferase; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific)
  • [Other-IDs] NLM/ PMC2044514
  •  go-up   go-down


56. Fredriksson-Ahomaa M, Naglic T, Turk N, Seol B, Grabarević Z, Bata I, Perkovic D, Stolle A: Yersiniosis in zoo marmosets (Callitrix jacchuss) caused by Yersinia enterocolitica 4/O:3. Vet Microbiol; 2007 Apr 15;121(3-4):363-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathomorphological diagnosis of the female (born in 1997) and the male (born in 1995) marmoset, was disseminated miliary necrosis of the liver. Y. enterocolitica 4/O:3 was isolated from both livers showing that monkeys are susceptible to this bioserotype.
  • The ail gene, which is an essential chromosomal virulence factor in pathogenic Y. enterocolitica isolates, was present in the marmoset isolates.

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223285.001).
  • [ISSN] 0378-1135
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / DNA, Bacterial
  •  go-up   go-down


57. Kolodziejek AM, Schnider DR, Rohde HN, Wojtowicz AJ, Bohach GA, Minnich SA, Hovde CJ: Outer membrane protein X (Ail) contributes to Yersinia pestis virulence in pneumonic plague and its activity is dependent on the lipopolysaccharide core length. Infect Immun; 2010 Dec;78(12):5233-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outer membrane protein X (Ail) contributes to Yersinia pestis virulence in pneumonic plague and its activity is dependent on the lipopolysaccharide core length.
  • Here, we tested the contribution of OmpX to disease progression in the fully virulent Y. pestis CO92 strain by engineering a deletion mutant and comparing its ability in mediating pneumonic plague to that of the wild type in two animal models.
  • The deletion of OmpX delayed the time to death up to 48 h in a mouse model and completely attenuated virulence in a rat model of disease.
  • The rat model, which is most similar to humans, highlighted the critical role of serum resistance in disease.

  • MedlinePlus Health Information. consumer health - Plague.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Structure. 2000 Jun 15;8(6):585-92 [10873859.001]
  • [Cites] Infect Immun. 2010 Jun;78(6):2644-52 [20368351.001]
  • [Cites] Microb Pathog. 2001 Feb;30(2):49-57 [11162185.001]
  • [Cites] FEMS Microbiol Lett. 2001 Apr 13;197(2):229-33 [11313139.001]
  • [Cites] Infect Immun. 2002 Feb;70(2):491-7 [11796574.001]
  • [Cites] Trends Microbiol. 2002 Feb;10(2):74-9 [11827808.001]
  • [Cites] Infect Immun. 2003 Jul;71(7):3673-81 [12819047.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Oct;29(4):432-8 [14500254.001]
  • [Cites] Mol Microbiol. 2004 Jan;51(1):215-25 [14651623.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(5):1363-73 [15165239.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):27-30 [15225603.001]
  • [Cites] J Bacteriol. 1966 Mar;91(3):953-62 [5929770.001]
  • [Cites] J Bacteriol. 1982 Aug;151(2):718-22 [7047495.001]
  • [Cites] Microbiol Rev. 1985 Mar;49(1):1-32 [2580220.001]
  • [Cites] J Bacteriol. 1990 Nov;172(11):6568-72 [2172217.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):161-7 [1702778.001]
  • [Cites] Infect Immun. 1991 Mar;59(3):1106-11 [1997413.001]
  • [Cites] J Bacteriol. 1992 Jan;174(1):84-91 [1729227.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):953-64 [1522243.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):5183-6 [7927803.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):799-804 [7836315.001]
  • [Cites] Infect Immun. 1995 Jul;63(7):2541-8 [7790067.001]
  • [Cites] Science. 1996 Jan 5;271(5245):64-7 [8539601.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 May;37(6):976-86 [8631641.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;216:39-81 [8791735.001]
  • [Cites] Infect Immun. 1997 Sep;65(9):3638-43 [9284130.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11059-64 [9736689.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):5114-9 [9988760.001]
  • [Cites] Science. 1954 Jun 18;119(3103):877 [13168383.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2232-44 [15784567.001]
  • [Cites] Biochem Soc Trans. 2005 Apr;33(Pt 2):331-4 [15787599.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1427-39 [15855643.001]
  • [Cites] Infect Immun. 2005 Nov;73(11):7324-31 [16239530.001]
  • [Cites] J Endotoxin Res. 2006;12(1):3-9 [16420739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5526-30 [16567636.001]
  • [Cites] Protein Sci. 2006 Apr;15(4):884-9 [16522795.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1066-73 [16980981.001]
  • [Cites] Infect Immun. 2006 Oct;74(10):5636-44 [16988239.001]
  • [Cites] Science. 2007 Jan 26;315(5811):509-13 [17255510.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L748-59 [17071722.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Appl Environ Microbiol. 2007 Sep;73(18):5750-9 [17644638.001]
  • [Cites] Adv Exp Med Biol. 2007;603:88-96 [17966406.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):578-87 [18025093.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3426-35 [18292569.001]
  • [Cites] J Pept Sci. 2008 Apr;14(4):535-43 [17985396.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] Microbiology. 2008 Jul;154(Pt 7):2131-8 [18599840.001]
  • [Cites] Infect Immun. 2009 Jan;77(1):317-26 [18936182.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):825-36 [19064637.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):910-21 [19164505.001]
  • [Cites] Vaccine. 2008 Dec 30;26 Suppl 8:I62-6 [19388167.001]
  • [Cites] PLoS One. 2009;4(6):e6000 [19543392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3070-5 [20133627.001]
  • [Cites] Infect Immun. 2000 Aug;68(8):4523-30 [10899851.001]
  • (PMID = 20837715.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI057141; United States / NCRR NIH HHS / RR / P20 RR016454; United States / NCRR NIH HHS / RR / P20 RR015587; United States / NIAID NIH HHS / AI / U54AI57141; United States / NCRR NIH HHS / RR / P20 RR15587
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Lipopolysaccharides; 0 / Virulence Factors
  • [Other-IDs] NLM/ PMC2981323
  •  go-up   go-down


58. Polydorides AD, Mukherjee B, Gruber SB, McKenna BJ, Appelman HD, Greenson JK: Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer. Am J Surg Pathol; 2008 Nov;32(11):1661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer.
  • Patients with hereditary nonpolyposis colorectal cancer syndrome (HNPCC) develop microsatellite-unstable colorectal cancers that tend to be more proximally located and are histologically more likely to show high numbers of tumor-infiltrating lymphocytes, a lack of dirty necrosis, mucinous or poor differentiation, and a Crohn-like host immune response, when compared with microsatellite-stable cancers.
  • Adenomas from HNPCC patients were more likely to contain high numbers of adenoma-infiltrating lymphocytes (AILs) with 12 of 16 (75%) adenomas having >or=5 AILs per high-power field (HPF) as opposed to 4 of 32 (12%) adenomas in the control group (P=0.00003).
  • Therefore, increased numbers of AILs and decreased numbers of apoptoses in colorectal adenomas are simple and inexpensive markers that raise the possibility of HNPCC.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62 [9392616.001]
  • [Cites] Semin Surg Oncol. 1995 Nov-Dec;11(6):406-10 [8607009.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):139-43 [15654793.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2525-35 [15735733.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1143-9 [15842591.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1150-3 [15842592.001]
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):17-24 [10963375.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2417-22 [11413533.001]
  • [Cites] Gut. 2002 Feb;50(2):228-34 [11788565.001]
  • [Cites] Gut. 2002 Mar;50(3):382-6 [11839719.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):563-70 [12717242.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1407-17 [14576473.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] Gut. 1995 Mar;36(3):385-90 [7698698.001]
  • [Cites] J Pathol. 1995 May;176(1):37-44 [7616355.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):160-70 [15858139.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1851-60 [15872200.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1095-101 [15731775.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):80-93; discussion 94-5 [16284887.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):831-8 [16784982.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):632-41 [16511680.001]
  • [Cites] JAMA. 2006 Sep 27;296(12):1507-17 [17003399.001]
  • [Cites] Int J Colorectal Dis. 2007 Jul;22(7):739-48 [17109103.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1093-8 [17919485.001]
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1660-8 [17999188.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3221-7 [10652615.001]
  • [Cites] In Vivo. 1995 May-Jun;9(3):173-6 [8562876.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):627-34 [8616753.001]
  • [Cites] In Vivo. 1997 Sep-Oct;11(5):393-4 [9427041.001]
  • (PMID = 18753941.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA081488
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS417252; NLM/ PMC3500084
  •  go-up   go-down


59. Bhaduri S, Wesley IV, Bush EJ: Prevalence of pathogenic Yersinia enterocolitica strains in pigs in the United States. Appl Environ Microbiol; 2005 Nov;71(11):7117-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of ail-positive Y. enterocolitica was determined in samples using both a fluorogenic 5' nuclease PCR assay and a culture method.
  • Forty-one of 77 premises (53.25%) contained at least one fecal sample positive for the ail sequence.
  • Among 77 premises, the PCR assay revealed a significantly (P < 0.05) higher percentage (46.75%, n = 36 sites) of samples positive for the pathogen (ail sequence) than the culture method (22.08%, n = 17 sites).
  • [MeSH-major] Bacterial Proteins / genetics. Disease Reservoirs. Feces / microbiology. Swine / microbiology. Yersinia enterocolitica / classification. Yersinia enterocolitica / pathogenicity

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):3750-5 [10966386.001]
  • [Cites] J Food Prot. 2001 Mar;64(3):355-60 [11252479.001]
  • [Cites] J Food Prot. 2001 Sep;64(9):1352-61 [11563512.001]
  • [Cites] Mol Cell Probes. 2003 Apr-Jun;17(2-3):99-105 [12788031.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):1007-9 [12967503.001]
  • [Cites] Vet Microbiol. 1983 Oct;8(5):469-83 [6649406.001]
  • [Cites] Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25 [10511517.001]
  • [Cites] N Engl J Med. 1990 Apr 5;322(14):984-7 [2314448.001]
  • [Cites] Appl Environ Microbiol. 1997 May;63(5):1657-60 [9143098.001]
  • [Cites] Appl Environ Microbiol. 1997 Dec;63(12):4952-5 [9406416.001]
  • [Cites] Mol Cell Probes. 1998 Apr;12(2):79-83 [9633042.001]
  • [Cites] J Food Prot. 1998 Jun;61(6):677-82 [9709248.001]
  • [Cites] Can J Vet Res. 1999 Apr;63(2):96-100 [10369565.001]
  • [Cites] Appl Environ Microbiol. 1988 Apr;54(4):851-4 [3377499.001]
  • (PMID = 16269749.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / DNA, Bacterial; EC 2.7.7.- / Taq Polymerase
  • [Other-IDs] NLM/ PMC1287643
  •  go-up   go-down


60. Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CP: Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit Pathw Cardiol; 2010 Mar;9(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Costs for each patient were calculated based on diagnosis-related groups-specific Medicare reimbursement rates for all hospitalizations and the average wholesale price of clopidogrel.
  • Cost per event prevented and cost per life year gained (LYG) were calculated using standard methods.
  • The estimate of LYG due to clopidogrel therapy was based on recurrent myocardial infarction and death outcomes.
  • The bootstrap method was used to produce bias-corrected confidence intervals for cost and efficacy estimates as well as the cost per LYG ratio.
  • Even in a sensitivity analysis accounting for higher long-term medical costs due to greater life expectancy, clopidogrel remained under $6000 per LYG.
  • Clopidogrel therapy was dominant in 35% of the bootstrap simulations and cost less than $50,000 per LYG in 67% of simulations.
  • [MeSH-minor] Adolescent. Adult. Aged. Cost-Benefit Analysis. Diagnosis-Related Groups / economics. Female. Hospital Costs. Humans. Male. Medicare / economics. Middle Aged. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Recurrence. Thrombolytic Therapy / economics. United States

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20215905.001).
  • [ISSN] 1535-2811
  • [Journal-full-title] Critical pathways in cardiology
  • [ISO-abbreviation] Crit Pathw Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine
  •  go-up   go-down


61. Heslop HE: Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program; 2005;:260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV-associated lymphomas occurring in individuals who do not have a known immunodeficiency include NK and T malignancies with cytotoxic phenotypes, sporadic cases of B-NHL and lymphomatoid granulomatosis.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304390.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA094237; United States / NCI NIH HHS / CA / CA61384; United States / NCI NIH HHS / CA / P01 CA94237; United States / NCRR NIH HHS / RR / RR00188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Tilson L, Usher C, Butler K, Fitzsimons J, O'Hare F, Cotter S, O'Flanagan D, Johnson H, Barry M: Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Value Health; 2008 Sep-Oct;11(5):898-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The baseline incremental cost-effectiveness ratio was 249,591 euros/life years gained (LYG), which reduced to 5997 euros/LYG when the effect of herd immunity was included.

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489504.001).
  • [ISSN] 1524-4733
  • [Journal-full-title] Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • [ISO-abbreviation] Value Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pneumococcal Vaccines; 0 / Vaccines, Conjugate
  •  go-up   go-down


63. Tsang TM, Felek S, Krukonis ES: Ail binding to fibronectin facilitates Yersinia pestis binding to host cells and Yop delivery. Infect Immun; 2010 Aug;78(8):3358-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ail binding to fibronectin facilitates Yersinia pestis binding to host cells and Yop delivery.
  • Yersinia pestis, the causative agent of plague, evades host immune responses and rapidly causes disease.
  • The Y. pestis adhesin Ail mediates host cell binding and is critical for Yop delivery.
  • To identify the Ail receptor(s), Ail was purified following overexpression in Escherichia coli.
  • Ail bound specifically to fibronectin, an extracellular matrix protein with the potential to act as a bridge between Ail and host cells.
  • Ail expressed by E. coli also mediated binding to purified fibronectin, and Ail-mediated E. coli adhesion to host cells was dependent on fibronectin.
  • Ail expressed by Y. pestis bound purified fibronectin, as did the Y. pestis adhesin plasminogen activator (Pla).
  • However, a KIM5 Delta ail mutant had decreased binding to host cells, while a KIM5 Delta pla mutant had no significant defect in adhesion.
  • Furthermore, treatment with antifibronectin antibodies decreased Ail-mediated adhesion by KIM5 and the KIM5 Delta pla mutant, indicating that the Ail-fibronectin interaction was important for cell binding.
  • Finally, antifibronectin antibodies inhibited the KIM5-mediated cytotoxicity of host cells in an Ail-dependent fashion.
  • These data indicate that Ail is a key adhesin that mediates binding to host cells through interaction with fibronectin on the surface of host cells, and this interaction is important for Yop delivery by Y. pestis.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):241-53 [9531562.001]
  • [Cites] Infect Immun. 1998 Sep;66(9):4545-8 [9712817.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5755-62 [9826351.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] PLoS Pathog. 2008;4(8):e1000140 [18769718.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):825-36 [19064637.001]
  • [Cites] Microbiology. 2009 Feb;155(Pt 2):498-512 [19202098.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):522-4 [3043229.001]
  • [Cites] Mol Microbiol. 1989 Mar;3(3):329-37 [2568575.001]
  • [Cites] Matrix Biol. 1999 Jun;18(3):211-23 [10429941.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17837-42 [15598742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3375-80 [16488979.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):158-62 [16923070.001]
  • [Cites] Microbes Infect. 2006 Jul;8(8):2291-8 [16782385.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1272-9 [17178780.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1301-9 [10545325.001]
  • [Cites] Mol Microbiol. 2000 Aug;37(3):515-27 [10931345.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):659-71 [11089914.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):69-72 [11522299.001]
  • [Cites] FEBS Lett. 2001 Aug 31;504(3):173-8 [11532450.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):4880-91 [12183532.001]
  • [Cites] J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3 [12244123.001]
  • [Cites] Microb Pathog. 2002 Dec;33(6):265-77 [12495673.001]
  • [Cites] J Lipid Res. 2003 Feb;44(2):320-30 [12576514.001]
  • [Cites] Curr Opin Infect Dis. 2003 Jun;16(3):225-9 [12821812.001]
  • [Cites] J Clin Invest. 1977 Oct;60(4):855-65 [19499.001]
  • [Cites] Int J Cancer. 1977 Jul 15;20(1):1-5 [903179.001]
  • [Cites] FEBS Lett. 1979 Jan 15;97(2):221-4 [761627.001]
  • [Cites] Science. 1980 Aug 22;209(4459):927-9 [7403857.001]
  • [Cites] Cell. 1981 Oct;26(2 Pt 2):259-67 [6174240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jan;80(1):137-41 [6218503.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(11):3471-5 [6374658.001]
  • [Cites] J Biol Chem. 1985 Apr 10;260(7):4492-500 [3920218.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Adv Exp Med Biol. 2007;603:97-105 [17966407.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e3 [18193942.001]
  • [Cites] Cell. 1990 Mar 9;60(5):861-71 [2311122.001]
  • [Cites] Mol Microbiol. 1990 Apr;4(4):657-67 [2191183.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Methods Enzymol. 1990;185:60-89 [2199796.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):86-93 [1846140.001]
  • [Cites] Gene. 1991 Jan 2;97(1):39-47 [1847347.001]
  • [Cites] J Biol Chem. 1991 Jul 15;266(20):12840-3 [1677003.001]
  • [Cites] J Bacteriol. 1991 Sep;173(17):5298-307 [1679429.001]
  • [Cites] Mol Microbiol. 1991 Jun;5(6):1439-45 [1686292.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Mol Microbiol. 1991 Dec;5(12):3063-72 [1809845.001]
  • [Cites] Infect Immun. 1992 Jul;60(7):3021-4 [1612772.001]
  • [Cites] J Gen Microbiol. 1992 Aug;138 Pt 8:1679-87 [1527508.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Annu Rev Microbiol. 1994;48:585-617 [7826020.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):799-804 [7836315.001]
  • [Cites] J Bacteriol. 1995 Oct;177(20):5997-6000 [7592356.001]
  • [Cites] Infect Immun. 1996 Jan;64(1):375-9 [8557370.001]
  • [Cites] EMBO J. 1996 Mar 1;15(5):989-98 [8605894.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1231-3 [8703058.001]
  • [Cites] FEMS Immunol Med Microbiol. 1996 May;14(1):53-7 [8804976.001]
  • [Cites] Mol Microbiol. 1997 May;24(3):499-510 [9179844.001]
  • [Cites] Mol Microbiol. 1997 Jun;24(5):953-63 [9220003.001]
  • [Cites] Mol Microbiol. 1998 Mar;27(5):953-65 [9535085.001]
  • (PMID = 20498264.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Fibronectins; 0 / Recombinant Proteins; 0 / Virulence Factors
  • [Other-IDs] NLM/ PMC2916272
  •  go-up   go-down


64. Lee KS, Groshong SD, Cool CD, Kleinschmidt-DeMasters BK, van Dyk LF: Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease. Cancer Res; 2009 Jul 1;69(13):5481-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease.
  • Here, we show that gammaHV68-infected IFNgamma receptor-deficient (IFNgammaR(-/-)) mice uniformly develop angiocentric inflammatory lesions in the lung.
  • By 12 months of infection, 80% of mice had lymphoid hyperplasia or pulmonary lymphoma; 45% of infected mice developed frank tumors between 5 and 12 months postinfection, with some mice showing systemic involvement.
  • This distinct combination of latent infection and defined host defect led to a specific and consistent lymphoproliferative disease.
  • Significantly, this mouse model of virus-associated pulmonary B-cell lymphoma closely mimics the full spectrum of human lymphomatoid granulomatosis, an EBV-associated malignancy with no effective treatment.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1111-20 [11688570.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Virol. 2002 Jul;76(14):7125-32 [12072512.001]
  • [Cites] J Virol. 2003 May;77(9):5118-26 [12692214.001]
  • [Cites] Pediatr Nephrol. 2003 Aug;18(8):838-42 [12802639.001]
  • [Cites] Histopathology. 2004 Jan;44(1):69-76 [14717672.001]
  • [Cites] Hum Pathol. 1972 Dec;3(4):457-558 [4638966.001]
  • [Cites] Cancer. 1979 Jan;43(1):360-73 [761171.001]
  • [Cites] Pathology. 1979 Jul;11(3):537-50 [523188.001]
  • [Cites] Jpn J Clin Oncol. 1989 Sep;19(3):249-57 [2681886.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Science. 1993 Mar 19;259(5102):1742-5 [8456301.001]
  • [Cites] Am J Pathol. 1994 Oct;145(4):818-26 [7943173.001]
  • [Cites] J Gen Virol. 1996 Apr;77 ( Pt 4):627-30 [8627250.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4531-7 [8639820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] J Virol. 1996 Oct;70(10):6775-80 [8794315.001]
  • [Cites] J Virol. 1997 May;71(5):3916-21 [9094668.001]
  • [Cites] J Virol. 1997 Aug;71(8):5894-904 [9223479.001]
  • [Cites] Curr Opin Immunol. 1997 Aug;9(4):477-83 [9287187.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4099-105 [9354680.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1346-53 [9396604.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):347-56 [9578085.001]
  • [Cites] Eur Respir J. 1998 Mar;11(3):779-83 [9596137.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):1941-51 [9625754.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Virol. 2000 Apr;74(8):3659-67 [10729142.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):1074-81 [10878386.001]
  • [Cites] J Virol. 2000 Aug;74(16):7451-61 [10906198.001]
  • [Cites] J Virol. 2000 Dec;74(23):11304-10 [11070030.001]
  • [Cites] Ann Hematol. 2001 Mar;80(3):174-7 [11320904.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2117-25 [11395389.001]
  • [Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]
  • [Cites] J Virol. 1999 Mar;73(3):2321-32 [9971815.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):79-81 [10037054.001]
  • [Cites] Virology. 1999 Sep 1;261(2):173-9 [10497103.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1558-65 [15498860.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L711-21 [15734789.001]
  • [Cites] J Virol. 2005 Dec;79(23):14668-79 [16282467.001]
  • [Cites] J Virol. 2006 Jan;80(1):192-200 [16352543.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):371-3 [16389950.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2485-93 [16760449.001]
  • [Cites] J Clin Exp Hematop. 2006 Mar;46(1):5-10 [17058803.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Jun 1;175(11):1139-50 [17363768.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] J Exp Med. 2002 Apr 1;195(7):931-40 [11927636.001]
  • (PMID = 19531651.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103632-03; United States / NCI NIH HHS / CA / R01 CA103632; United States / NCI NIH HHS / CA / R01 CA103632-03S1; United States / NCI NIH HHS / CA / R01 CA103632-03; United States / NIAID NIH HHS / AI / T32 AI007405; United States / NCI NIH HHS / CA / CA103632-03S1; United States / NCI NIH HHS / CA / R01 CA103632-05S1; United States / NIAID NIH HHS / AI / T32 AI007405-18; United States / NCI NIH HHS / CA / R01 CA103632-04; United States / NIAID NIH HHS / AI / T32 AI007537; United States / NCI NIH HHS / CA / CA103632-05; United States / NCI NIH HHS / CA / R01 CA103632-05; United States / NCI NIH HHS / CA / CA103632-04S1; United States / NCI NIH HHS / CA / CA103632-04; United States / NCI NIH HHS / CA / R01 CA103632-04S1; United States / NIAID NIH HHS / AI / T32 AI07537-09; United States / NCI NIH HHS / CA / CA103632-05S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS117880; NLM/ PMC2712112
  •  go-up   go-down


65. Chirico G, Ravasio R, Sbarigia U: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr; 2009;35(1):4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We considered Life-Years Gained (LYGs), Quality-Adjusted Life-Years (QALYs) and direct medical costs (pharmacological treatment, hospitalization, recurrences for wheezing, etc.).
  • LYGs and QALYs were based on the results of a double blind cohort study with prospective follow-up and direct medical costs were based on Italian treatment patterns.
  • We calculated for palivizumab versus no prophylaxis the incremental cost per LYG and per QALY gained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Infect Dis J. 1998 Sep;17(9):787-91 [9779762.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):541-5 [10470697.001]
  • [Cites] J Infect Dis. 1997 Nov;176(5):1215-24 [9359721.001]
  • [Cites] Med Care. 1996 Jul;34(7):702-22 [8676608.001]
  • [Cites] Risk Anal. 1995 Jun;15(3):369-90 [7604170.001]
  • [Cites] Arch Dis Child. 2004 Jul;89(7):673-8 [15210503.001]
  • [Cites] Pediatr Pulmonol. 2004 Aug;38(2):155-60 [15211700.001]
  • [Cites] Thorax. 2004 Jun;59(6):512-6 [15170037.001]
  • [Cites] J Pediatr. 2003 Nov;143(5 Suppl):S150-6 [14615714.001]
  • [Cites] Pharmacoeconomics. 2001;19(11):1103-9 [11735677.001]
  • [Cites] Am J Respir Crit Care Med. 2000 May;161(5):1501-7 [10806145.001]
  • [Cites] J Allergy Clin Immunol. 1999 Nov;104(5):957-63 [10550739.001]
  • [Cites] J Pediatr. 2007 Jul;151(1):34-42, 42.e1 [17586188.001]
  • [Cites] Pharmacoeconomics. 2007;25(1):55-71 [17192118.001]
  • [Cites] An Pediatr (Barc). 2006 Oct;65(4):316-24 [17020726.001]
  • [Cites] Arch Pediatr Adolesc Med. 2006 Oct;160(10):1070-6 [17018467.001]
  • [Cites] Pediatr Allergy Immunol. 2005 Aug;16(5):386-92 [16101930.001]
  • [Cites] Pharmacoeconomics. 2004;22 Suppl 4:5-10 [15876007.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Jan 15;171(2):137-41 [15516534.001]
  • [Cites] Lancet. 1999 Sep 4;354(9181):847-52 [10485741.001]
  • [Cites] Pediatr Infect Dis J. 1998 Feb;17(2):110-5 [9493805.001]
  • (PMID = 19490659.001).
  • [ISSN] 1824-7288
  • [Journal-full-title] Italian journal of pediatrics
  • [ISO-abbreviation] Ital J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2687544
  •  go-up   go-down


66. Jaffre S, Jardin F, Dominique S, Duet E, Hubscher P, Genevois A, Corne F, Bota S, Nouvet G, Thiberville L: Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab. Eur Respir J; 2006 Mar;27(3):644-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab.
  • Lymphomatoid granulomatosis is a rare angiocentric and angiodestructive disease, which commonly involves the lungs but also the brain, kidneys, liver and skin.
  • This report describes the case of a 33-yr-old female with an aggressive form of lymphoid granulomatosis treated with an anti-CD20 antibody.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hemoptysis / etiology. Immunologic Factors / therapeutic use. Lymphomatoid Granulomatosis / complications. Lymphomatoid Granulomatosis / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507866.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


67. Ishiura H, Morikawa M, Hamada M, Watanabe T, Kako S, Chiba S, Motokura T, Hangaishi A, Shibahara J, Akahane M, Goto J, Kwak S, Kurokawa M, Tsuji S: Lymphomatoid granulomatosis involving central nervous system successfully treated with rituximab alone. Arch Neurol; 2008 May;65(5):662-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis involving central nervous system successfully treated with rituximab alone.
  • OBJECTIVE: To report the successful treatment of a patient with lymphomatoid granulomatosis (LYG), a rare Epstein-Barr virus-positive lymphoproliferative disorder, using rituximab (anti-CD20 monoclonal antibody).
  • The prognosis for LYG has been reported to be poor, and no satisfactory treatment has been established.
  • Because central nervous system (CNS) involvement of LYG has been known to show poor prognosis, the establishment of an effective treatment for CNS LYG with mild adverse effects is desired.
  • PATIENT: A 48-year-old Japanese man presenting with slowly progressive spastic paraparesis diagnosed as LYG involving the CNS and lungs.
  • Main Outcome Measure Improvement of the lesions on imaging.
  • RESULTS: The neurological signs resolved and the lesions in the CNS and lungs were mostly diminished after the rituximab monotherapy without any adverse effects.
  • CONCLUSION: Rituximab monotherapy was effective in treating the patient; hence, rituximab should be considered as the initial treatment against LYG involving the CNS.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Central Nervous System Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lymphomatoid Granulomatosis / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474745.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


68. Kiryu S, Okubo T, Takeuchi K, Inoue Y, Endo T, Odawara T, Nakamura T, Aoki S, Ohtomo K: Magnetic resonance imaging and diffusion tensor analysis of lymphomatoid granulomatosis of the brain. Acta Radiol; 2006 Jun;47(5):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging and diffusion tensor analysis of lymphomatoid granulomatosis of the brain.
  • We present the case of a 56-year-old man suffering from acquired immune deficiency syndrome associated with lymphomatoid granulomatosis.
  • Stereotactic brain biopsy was performed and lymphomatoid granulomatosis was confirmed.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Lymphomatoid Granulomatosis / diagnosis


69. Jordan K, Grothey A, Grothe W, Kegel T, Wolf HH, Schmoll HJ: Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. Eur J Haematol; 2005 Mar;74(3):263-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy.
  • Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder.
  • In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis.
  • This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphomatoid Granulomatosis / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Radiotherapy, Adjuvant. Rituximab

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2007 Feb;78(2):176-7 [17313566.001]
  • [CommentIn] Eur J Haematol. 2005 Aug;75(2):172-3 [16000136.001]
  • (PMID = 15693798.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


70. Best drugs for what ails you: the brands to buy--and those to skip. Consum Rep; 2009 Sep;74(9):14-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best drugs for what ails you: the brands to buy--and those to skip.

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Common Cold.
  • MedlinePlus Health Information. consumer health - Cough.
  • MedlinePlus Health Information. consumer health - Flu.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • MedlinePlus Health Information. consumer health - Over-the-Counter Medicines.
  • MedlinePlus Health Information. consumer health - Sore Throat.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. DEXTROMETHORPHAN .
  • Hazardous Substances Data Bank. CHLORPHENIRAMINE .
  • Hazardous Substances Data Bank. OXYMETAZOLINE .
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • Hazardous Substances Data Bank. LORATADINE .
  • Hazardous Substances Data Bank. Cetirizine .
  • Hazardous Substances Data Bank. PSEUDOEPHEDRINE .
  • Hazardous Substances Data Bank. GUAIFENESIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821542.001).
  • [ISSN] 0010-7174
  • [Journal-full-title] Consumer reports
  • [ISO-abbreviation] Consum Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Expectorants; 0 / Histamine Antagonists; 0 / Influenza Vaccines; 0 / Nonprescription Drugs; 0 / Propiophenones; 078A24Q30O / dyclonine; 362O9ITL9D / Acetaminophen; 3U6IO1965U / Chlorpheniramine; 451W47IQ8X / Sodium Chloride; 495W7451VQ / Guaifenesin; 7355X3ROTS / Dextromethorphan; 7AJO3BO7QN / Loratadine; 7CUC9DDI9F / Pseudoephedrine; 8GTS82S83M / Diphenhydramine; 8VLN5B44ZY / Oxymetazoline; PDC6A3C0OX / Glycerol; WK2XYI10QM / Ibuprofen; YO7261ME24 / Cetirizine
  •  go-up   go-down


71. Poonawalla T, Colome-Grimmer MI, Kelly B: Ulcerative sarcoidosis in the legs with granulomatous vasculitis. Clin Exp Dermatol; 2008 May;33(3):282-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulomatous vasculitis, classically associated with Wegener's granulomatosis, lymphomatoid granulomatosis, or Churg-Strauss syndrome, is also commonly described in pulmonary sarcoidosis.


72. French E, Rodriguez-Palacios A, LeJeune JT: Enteric bacterial pathogens with zoonotic potential isolated from farm-raised deer. Foodborne Pathog Dis; 2010 Sep;7(9):1031-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ail virulence gene could not be amplified from any of the Y. enterocolitica isolates recovered.
  • [MeSH-minor] Agriculture. Animals. Clostridium difficile / isolation & purification. Disease Reservoirs / microbiology. Disease Reservoirs / veterinary. Escherichia coli / isolation & purification. Feces / microbiology. Foodborne Diseases / microbiology. Listeria monocytogenes / isolation & purification. Meat / microbiology. Salmonella enterica / isolation & purification. Yersinia enterocolitica / isolation & purification

  • MedlinePlus Health Information. consumer health - Animal Diseases and Your Health.
  • MedlinePlus Health Information. consumer health - Pet Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575673.001).
  • [ISSN] 1556-7125
  • [Journal-full-title] Foodborne pathogens and disease
  • [ISO-abbreviation] Foodborne Pathog. Dis.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Ramírez RE, Torres-González LC, Hernández A, García A, Sánchez EM: Conductivity and viscosity behavior of asymmetric phosphonium iodides. J Phys Chem B; 2010 Apr 1;114(12):4271-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We plotted the conductivity and viscosity data of APIs according to Walden's rule and found that they can be classified as an associated ionic liquid (AIL), an intermediate between a true ionic liquid and a molecular species.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205443.001).
  • [ISSN] 1520-5207
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Bischof M, Leuppi JD, Sendi P: Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients. Expert Rev Pharmacoecon Outcomes Res; 2006 Apr;6(2):171-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Costs were expressed in 2004 Swiss Francs (CHF) and effects as life-years gained (LYG).
  • In patients undergoing hip fracture surgery, the incremental cost-effectiveness ratio of extended 4-week fondaparinux prophylaxis versus a 1-week regimen was CHF 2801/LYG after 30 days, with cost-savings after 5 years.
  • In patients undergoing THR, the respective incremental cost-effectiveness ratio of extended fondaparninux prophylaxis was CHF 20,294/LYG after 30 days, with cost-savings after 5 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528553.001).
  • [ISSN] 1744-8379
  • [Journal-full-title] Expert review of pharmacoeconomics & outcomes research
  • [ISO-abbreviation] Expert Rev Pharmacoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Berg SE, Downs LH, Torigian DA, Chong EA, Tsai DE, Wasik MA, Schuster SJ: Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene. Cancer Biol Ther; 2008 Oct;7(10):1544-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene.
  • Lymphomatoid granulomatosis is a rare lymphoproliferative disorder involving the lungs, skin and other organs.
  • Advanced-stage disease does not tend to respond well to cytotoxic chemotherapy and is associated with a poor prognosis.
  • We present a case of successful treatment of relapsed lymphomatoid granulomatosis with bexarotene, a novel retinoid agent.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lymphomatoid Granulomatosis / drug therapy. Lymphomatoid Granulomatosis / pathology. Tetrahydronaphthalenes / pharmacology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836291.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Retinoids; 0 / Tetrahydronaphthalenes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; A61RXM4375 / bexarotene; VAP-cyclo protocol
  •  go-up   go-down


76. Huang Y, Wang X, Cui Z, Yang Y, Xiao Y, Tang L, Kan B, Xu J, Jing H: Possible use of ail and foxA polymorphisms for detecting pathogenic Yersinia enterocolitica. BMC Microbiol; 2010;10:211
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible use of ail and foxA polymorphisms for detecting pathogenic Yersinia enterocolitica.
  • BACKGROUND: Yersinia enterocolitica is an enteric pathogen that invades the intestinal mucosa and proliferates within the lymphoid follicles (Peyer's patches).
  • The attachment invasion locus (ail) mediates invasion by Y. enterocolitica and confers an invasive phenotype upon non-invasive E. coli; ail is the primary virulence factor of Y. enterocolitica.
  • Currently, ail is the primary target gene for nucleic acid detection of pathogenic Y. enterocolitica.
  • RESULTS: The genes ail and foxA in 271 pathogenic and 27 non-pathogenic Y. enterocolitica strains isolated from China and 10 reference strains were sequenced, aligned, compared to the ail and foxA sequences of Yersinia enterocolitica subsp. enterocolitica 8081 (Genbank: NC_008800), and analyzed for sequence polymorphism.
  • The ail from the 282 strains showed 3 sequence patterns: 277 strains of serotypes O:3, O:9 and O:5, 27 with identical nucleic acid sequences formed pattern A1; 4 strains of serotype 1B/O:8 with identical nucleic acid sequences formed pattern A2; and one Chinese isolate 2/O:9 formed pattern A3.
  • CONCLUSION: The ail and foxA loci of pathogenic Y. enterocolitica have been analyzed.
  • The ail sequence was highly conserved among the same serotype strains from different sources; and foxA was highly conserved among the pathogenic strains, although there was some sequence diversity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1998 May;180(9):2579-82 [9573216.001]
  • [Cites] J Am Chem Soc. 2005 Feb 2;127(4):1137-45 [15669853.001]
  • [Cites] Jpn J Infect Dis. 2005 Feb;58(1):31-3 [15728988.001]
  • [Cites] Int J Food Microbiol. 2008 Jul 31;125(3):259-66 [18541322.001]
  • [Cites] Appl Environ Microbiol. 2008 Oct;74(19):6060-7 [18708521.001]
  • [Cites] Zentralbl Bakteriol. 1993 Apr;278(2-3):416-24 [8347944.001]
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):3750-5 [10966386.001]
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):4131-5 [10966441.001]
  • [Cites] J Food Prot. 2001 Sep;64(9):1352-61 [11563512.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):105-16 [12563288.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1810-6 [12620874.001]
  • [Cites] J Med Microbiol. 2004 Nov;53(Pt 11):1065-8 [15496381.001]
  • [Cites] Infect Immun. 1975 Jan;11(1):164-70 [1116874.001]
  • [Cites] CRC Crit Rev Microbiol. 1977;5(2):211-41 [844324.001]
  • [Cites] J Bacteriol. 1979 Mar;137(3):1290-8 [108243.001]
  • [Cites] Annu Rev Microbiol. 1982;36:435-65 [6756294.001]
  • [Cites] Infect Immun. 1984 Oct;46(1):105-10 [6480101.001]
  • [Cites] J Med Microbiol. 1985 Apr;19(2):237-46 [3981611.001]
  • [Cites] J Bacteriol. 1987 Jun;169(6):2624-30 [3294800.001]
  • [Cites] Biochemistry. 1987 Aug 25;26(17):5471-7 [2823881.001]
  • [Cites] Infect Immun. 1989 Jan;57(1):121-31 [2642465.001]
  • [Cites] N Engl J Med. 1989 Jul 6;321(1):16-24 [2659991.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):1062-9 [1688838.001]
  • [Cites] Infect Immun. 1990 Apr;58(4):1059-64 [1690684.001]
  • [Cites] Gut. 1990 Sep;31(9):1011-5 [2210445.001]
  • [Cites] J Bacteriol. 1991 Jan;173(2):417-25 [1898928.001]
  • [Cites] J Bacteriol. 1992 Feb;174(3):1029-35 [1732192.001]
  • [Cites] Mol Microbiol. 1992 May;6(10):1309-21 [1640832.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Mol Microbiol. 1993 Apr;8(2):397-408 [8316088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6473-7 [8341658.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):257-76 [9105754.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):799-808 [9427409.001]
  • [Cites] J Bacteriol. 1998 Feb;180(3):538-46 [9457855.001]
  • (PMID = 20691098.001).
  • [ISSN] 1471-2180
  • [Journal-full-title] BMC microbiology
  • [ISO-abbreviation] BMC Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / FoxA protein, bacteria; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ PMC2924855
  •  go-up   go-down


77. Ho DK, Jarva H, Meri S: Human complement factor H binds to outer membrane protein Rck of Salmonella. J Immunol; 2010 Aug 1;185(3):1763-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the Rck homolog from Yersinia enterocolitica, Ail, has been shown to bind the complement regulatory protein factor H (fH).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622116.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins; 0 / Escherichia coli Proteins; 134632-13-6 / OmpX protein, E coli; 80295-65-4 / Complement Factor H; EC 3.- / Hydrolases
  •  go-up   go-down


78. Fredriksson-Ahomaa M, Meyer C, Bonke R, Stüber E, Wacheck S: Characterization of Yersinia enterocolitica 4/O:3 isolates from tonsils of Bavarian slaughter pigs. Lett Appl Microbiol; 2010 Apr;50(4):412-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Hundred and eighty-seven ail-positive Y. enterocolitica 4/O:3 isolates recovered from pigs originating from 31 Bavarian farms in 2000, 2003 and 2004 were characterized.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158605.001).
  • [ISSN] 1472-765X
  • [Journal-full-title] Letters in applied microbiology
  • [ISO-abbreviation] Lett. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Heresbach D, Chauvin P, Grolier J, Josselin JM: Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests. Eur J Gastroenterol Hepatol; 2010 Nov;22(11):1372-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incremental cost-effectiveness ratio of CTC and iFOBT were respectively 3204 and 5458 euro per life years gained (LYG), the ER for CTC was 0.22 and the ER for iFOBT was 2.08 colonoscopies per LYG.
  • In the probabilistic sensitivity analysis, compared with CTC, iFOBT strategy was cost-effective for 84.6% of simulations when we assumed a willingness to pay (WTP) of 20,000 euro/LYG.
  • However, iFOBT is the preferred screening strategy for a WTP greater than 6207 euro/LYG.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / economics. Colorectal Neoplasms / diagnosis. Health Care Costs. Intestinal Polyps / diagnosis. Mass Screening / economics. Occult Blood. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Aged. Colonic Polyps / diagnosis. Computer Simulation. Cost-Benefit Analysis. Female. France. Humans. Male. Markov Chains. Middle Aged. Models, Economic. Predictive Value of Tests


80. Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH: Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health; 2009 Mar-Apr;12(2):217-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adding survival benefit from avoiding FN mortality yielded an ICER of $110,000/life-year gained (LYG) or $116,000/quality-adjusted life-year (QALY) gained.
  • The most influential factors included FN case-fatality, FN relative risk reduction from primary prophylaxis, and age at diagnosis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673353.001).
  • [ISSN] 1524-4733
  • [Journal-full-title] Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • [ISO-abbreviation] Value Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


81. Kershaw P, Anderson L: Is a pan-Canadian early child development system possible? Yes, when we redress what ails Canadian culture. Paediatr Child Health; 2009 Dec;14(10):685-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is a pan-Canadian early child development system possible? Yes, when we redress what ails Canadian culture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119820.001).
  • [ISSN] 1918-1485
  • [Journal-full-title] Paediatrics & child health
  • [ISO-abbreviation] Paediatr Child Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2807815
  • [Keywords] NOTNLM ; Early childhood development / Outcomes / Social paediatrics
  •  go-up   go-down


82. Marcheix PS, Marcheix B, Siegler J, Bouillet P, Chaynes P, Valleix D, Mabit C: The anterior intermeniscal ligament of the knee: an anatomic and MR study. Surg Radiol Anat; 2009 Jun;31(5):331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purposes of this study were to identify the presence of the anterior intermeniscal ligament of the knee (AIL), to study its attachment patterns and relationships to other anatomic structures within the knee and to evaluate the potential association of its rupture with other pathology of the knee.
  • RESULTS: AIL was found in nine dissected knees with type I insertion in six cases, type II insertion in three cases.
  • The average distance between AIL and insertion of the anterior cruciate ligament was 12 mm (11-15 mm).
  • Concerning MR study, AIL was found in 34 cases (82.9%).
  • Four (9.75%) ruptures of the AIL were encountered.
  • Where AIL was intact, 14 patients presented meniscal lesions (46.6%).
  • Where AIL was ruptured, three patients presented meniscal lesions (75%).
  • CONCLUSION: The present study demonstrates through anatomical and MR studies that AIL is present in more than 80% of the cases with predominant type I insertion.
  • The association of meniscal and AIL lesions was highlighted demonstrating that AIL is not only an anatomical point of interest but also a clinical and surgical reality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Radiol Anat. 2008 Feb;30(1):5-9 [17989912.001]
  • [Cites] Eur Radiol. 2002 Apr;12(4):824-9 [11960233.001]
  • [Cites] J Radiol. 1989;70(4):265-77 [2677331.001]
  • [Cites] Arthroscopy. 1997 Dec;13(6):725-30 [9442326.001]
  • [Cites] Am J Sports Med. 1998 Jul-Aug;26(4):540-3 [9689375.001]
  • [Cites] Surg Radiol Anat. 2002 May;24(2):120-4 [12197021.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2002 Nov;10(6):343-6 [12444511.001]
  • [Cites] Anat Anz. 1974;135(1-2):35-42 [4479243.001]
  • [Cites] Am J Sports Med. 2000 Jan-Feb;28(1):74-6 [10653547.001]
  • [Cites] Invest Radiol. 1999 Sep;34(9):558-65 [10485070.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2008 Dec;16(12):1121-32 [18802689.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2006 Mar;14(3):204-13 [16235056.001]
  • (PMID = 19234659.001).
  • [ISSN] 1279-8517
  • [Journal-full-title] Surgical and radiologic anatomy : SRA
  • [ISO-abbreviation] Surg Radiol Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Percik R, Serr J, Segal G, Stienlauf S, Trau H, Shalmon B, Shimoni A, Sidi Y: Lymphomatoid granulomatosis: a diagnostic challenge. Isr Med Assoc J; 2005 Mar;7(3):198-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: a diagnostic challenge.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792271.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


84. Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ: Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine; 2007 May 4;25(18):3669-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our model projects a base-case incremental cost-effectiveness ratio (iCER) of euro14,000 (95% uncertainty interval (UI): 9,800-20,200) per quality adjusted life year (QALY) or euro15,600 (95% UI: 11,100-23,900) per life year gained (LYG).

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17360082.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Heptavalent Pneumococcal Conjugate Vaccine; 0 / Meningococcal Vaccines; 0 / Pneumococcal Vaccines
  •  go-up   go-down


85. Nole-Wilson S, Tranby TL, Krizek BA: AINTEGUMENTA-like (AIL) genes are expressed in young tissues and may specify meristematic or division-competent states. Plant Mol Biol; 2005 Mar;57(5):613-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AINTEGUMENTA-like (AIL) genes are expressed in young tissues and may specify meristematic or division-competent states.
  • We report expression analyses of seven Arabidopsis genes most closely related to the floral development gene AINTEGUMENTA (ANT) and show that all AINTEGUMENTA-like (AIL) genes are transcribed in multiple tissues during development.
  • Our results are consistent with AIL genes having roles in specification of meristematic or division-competent states.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1991 May;112(1):1-20 [1685111.001]
  • [Cites] Development. 2003 Dec;130(24):6001-12 [14573523.001]
  • [Cites] Curr Opin Plant Biol. 2003 Oct;6(5):430-40 [12972043.001]
  • [Cites] Science. 2003 Aug 1;301(5633):653-7 [12893945.001]
  • [Cites] Science. 1999 Mar 19;283(5409):1911-4 [10082464.001]
  • [Cites] Cell. 1991 Jun 14;65(6):991-1002 [1675158.001]
  • [Cites] J Exp Bot. 2001 May;52(358):1111-5 [11432927.001]
  • [Cites] Plant Cell. 2003 Nov;15(11):2730-41 [14555699.001]
  • [Cites] Plant Cell. 2000 Aug;12(8):1357-66 [10948255.001]
  • [Cites] Plant Cell. 2002 Dec;14(12):2985-94 [12468722.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):998-1009 [11798174.001]
  • [Cites] Plant Cell. 1990 Aug;2(8):755-67 [2152125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):942-7 [10639184.001]
  • [Cites] Cell. 1997 May 16;89(4):575-85 [9160749.001]
  • [Cites] Biol Chem. 1998 Jun;379(6):633-46 [9687012.001]
  • [Cites] Plant J. 2004 Nov;40(4):575-85 [15500472.001]
  • [Cites] Plant Cell. 2004 Sep;16(9):2265-77 [15319480.001]
  • [Cites] Plant Cell. 2001 Dec;13(12):2609-18 [11752375.001]
  • [Cites] Plant Cell. 1989 Dec;1(12):1195-1208 [12359889.001]
  • [Cites] Curr Top Dev Biol. 1999;45:155-205 [10332605.001]
  • [Cites] Development. 2003 Aug;130(16):3841-50 [12835399.001]
  • [Cites] Plant J. 2001 Sep;27(6):581-90 [11576441.001]
  • [Cites] Plant Cell. 2002 Aug;14(8):1737-49 [12172019.001]
  • [Cites] Development. 2000 Nov;127(22):4971-80 [11044410.001]
  • [Cites] Plant Cell. 1996 Feb;8(2):137-53 [8742706.001]
  • [Cites] Plant Cell. 1996 Aug;8(8):1277-89 [8776897.001]
  • [Cites] Plant Cell. 1994 Dec;6(12):1859-76 [7866029.001]
  • [Cites] Cell. 2004 Oct 1;119(1):109-20 [15454085.001]
  • [Cites] Plant Cell. 2003 Mar;15(3):694-705 [12615942.001]
  • [Cites] Curr Biol. 2002 Sep 3;12(17):1484-95 [12225663.001]
  • [Cites] Plant Cell. 1996 Feb;8(2):155-68 [8742707.001]
  • [Cites] Science. 2002 Nov 8;298(5596):1238-41 [12424380.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 1;31(7):1859-68 [12655002.001]
  • [Cites] Plant Cell. 1996 Apr;8(4):659-71 [8624440.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2022-5 [12893888.001]
  • [Cites] Dev Genes Evol. 2004 Mar;214(3):105-14 [14986134.001]
  • [Cites] Nucleic Acids Res. 1989 Mar 25;17(6):2362 [2468132.001]
  • [Cites] Nucleic Acids Res. 2001 Sep 15;29(18):3757-74 [11557808.001]
  • [Cites] Plant Cell. 1989 Jan;1(1):37-52 [2535466.001]
  • [Cites] Science. 2000 Dec 15;290(5499):2105-10 [11118137.001]
  • [Cites] Dev Genet. 1999 Sep;25(3):224-36 [10528263.001]
  • (PMID = 15988559.001).
  • [ISSN] 0167-4412
  • [Journal-full-title] Plant molecular biology
  • [ISO-abbreviation] Plant Mol. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AINTEGUMENTA protein, Arabidopsis; 0 / Arabidopsis Proteins; 0 / DNA, Bacterial; 0 / DNA-Binding Proteins; 0 / PLT1 protein, Arabidopsis; 0 / PLT2 protein, Arabidopsis; 0 / RNA, Messenger; 0 / T-DNA; 0 / Transcription Factor AP-2; 0 / Transcription Factors
  •  go-up   go-down


86. Zhang S, Lou Y, Amstein TM, Anyango M, Mohibullah N, Osoti A, Stancliffe D, King R, Iraqi F, Gershenfeld HK: Fine mapping of a major locus on chromosome 10 for exploratory and fear-like behavior in mice. Mamm Genome; 2005 May;16(5):306-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced intercross lines (AIL) and interval-specific congenic strains (ISCS) were used to fine map previously coarsely defined quantitative trait loci (QTL) on Chromosomes 1, 10, and 19, influencing behaviors in the open Field (OF) and light-dark (LD) paradigms in mice.
  • F12(A x B) AIL mice (N = 1130) were phenotyped, genotyped, and mapped.
  • The Chromosome 10 Exq1 and Chromosome 19 Exq4 loci mapped robustly in the AIL.
  • The replicated QTLs on Chromosome 1 failed to map in this AIL population.

  • COS Scholar Universe. author profiles.
  • GeneWeaver. GeneWeaver .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1787-92 [11172029.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):280-4 [9354790.001]
  • [Cites] Behav Genet. 1997 May;27(3):201-10 [9210791.001]
  • [Cites] Genomics. 1997 Nov 15;46(1):1-8 [9403052.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:228-37 [12610532.001]
  • [Cites] Behav Genet. 1978 Jan;8(1):3-13 [637827.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):331-4 [9354800.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Brain Res Bull. 2003 May 15;60(3):223-31 [12754084.001]
  • [Cites] Genetics. 1995 Jul;140(3):1111-27 [7672582.001]
  • [Cites] Science. 1981 Jul 10;213(4504):172-8 [7017931.001]
  • [Cites] Nat Genet. 1999 Mar;21(3):305-8 [10080185.001]
  • [Cites] J Neurosci. 1999 May 15;19(10 ):3731-8 [10234005.001]
  • [Cites] Genetics. 1998 Jun;149(2):999-1017 [9611209.001]
  • [Cites] Annu Rev Genet. 2001;35:303-39 [11700286.001]
  • [Cites] Science. 2004 Apr 16;304(5669):445-8 [15031436.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):19-24 [9425894.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1197-202 [15489855.001]
  • [Cites] Pharmacol Biochem Behav. 1981 Nov;15(5):695-9 [6118883.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3317-24 [12810665.001]
  • [Cites] Bioinformatics. 2002 Feb;18(2):339-40 [11847090.001]
  • [Cites] Curr Biol. 2001 May 15;11(10):725-34 [11378382.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):335-7 [9354801.001]
  • [Cites] Genomics. 2001 May 15;74(1):21-35 [11374899.001]
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):83-7 [12478479.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):221-5 [10700173.001]
  • [Cites] Genome Res. 2001 Sep;11(9):1549-52 [11544198.001]
  • [Cites] Genome Res. 2000 Jan;10(1):42-8 [10645948.001]
  • [Cites] Genetics. 2001 Jul;158(3):1217-26 [11454769.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):520-62 [12466850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12642-7 [14583591.001]
  • [Cites] Annu Rev Immunol. 2003;21:629-57 [12500978.001]
  • [Cites] Brain Res Bull. 2002 Jan 1;57(1):17-26 [11827733.001]
  • [Cites] Mamm Genome. 2003 Apr;14(4):223-30 [12682774.001]
  • [Cites] J Neurobiol. 2003 Jan;54(1):46-77 [12486698.001]
  • [Cites] Genetics. 1995 Mar;139(3):1455-61 [7768453.001]
  • [Cites] Mamm Genome. 1999 Apr;10(4):327-34 [10087288.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Nature. 2002 Mar 21;416(6878):326-30 [11907579.001]
  • [Cites] Genetics. 2000 Oct;156(2):899-911 [11014835.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):877-92 [12145742.001]
  • [Cites] Behav Genet. 1994 Mar;24(2):171-80 [8024534.001]
  • [Cites] Behav Brain Res. 1997 Apr;85(1):57-69 [9095342.001]
  • [Cites] Anim Behav. 1973 May;21(2):205-35 [4578750.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):129-36 [11752274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12649-54 [11050180.001]
  • [Cites] Mol Genet Genomics. 2002 Jan;266(5):821-6 [11810256.001]
  • [Cites] Immunol Today. 1997 Oct;18(10):472-7 [9357138.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):641-9 [11195461.001]
  • [Cites] Mamm Genome. 1998 Sep;9(9):688-94 [9716653.001]
  • (PMID = 16104379.001).
  • [ISSN] 0938-8990
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / R01-MH58882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers
  •  go-up   go-down


87. Peterkin A: Medical humanities for what ails us. CMAJ; 2008 Feb 26;178(5):648
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical humanities for what ails us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299558.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2244678
  •  go-up   go-down


88. Platt-Samoraj A, Ugorski M, Szweda W, Szczerba-Turek A, Wojciech K, Procajło Z: Analysis of the presence of ail, ystA and ystB genes in Yersinia enterocolitica strains isolated from aborting sows and aborted fetuses. J Vet Med B Infect Dis Vet Public Health; 2006 Sep;53(7):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the presence of ail, ystA and ystB genes in Yersinia enterocolitica strains isolated from aborting sows and aborted fetuses.
  • Forty-five Yersinia enterocolitica strains isolated from aborted fetuses and placentas and from vaginal and rectal swabs of aborting sows were subjected to serotyping, biochemical typing and polymerase chain reaction multiplex analyses to detect the presence of the ail, yst A and ystB genes.
  • As expected, the Y. enterocolitica strains of bioserotype 4/O:3 contained ail and ystA genes, while strains of biotype 1A contained only the ystB gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930279.001).
  • [ISSN] 0931-1793
  • [Journal-full-title] Journal of veterinary medicine. B, Infectious diseases and veterinary public health
  • [ISO-abbreviation] J. Vet. Med. B Infect. Dis. Vet. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Bacterial Toxins; 0 / Enterotoxins; 0 / heat-stable enterotoxin (Yersinia)
  •  go-up   go-down


89. Micol R, Tajahmady A, Lortholary O, Balkan S, Quillet C, Dousset JP, Chanroeun H, Madec Y, Fontanet A, Yazdanpanah Y: Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One; 2010;5(11):e13856
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A MARKOV DECISION TREE WAS USED TO COMPARE THE FOLLOWING STRATEGIES AT THE TIME OF HIV DIAGNOSIS: no intervention, one time systematic serum cryptococcal antigen (CRAG) screening and treatment of positive patients, and systematic primary prophylaxis with fluconazole.
  • After one year of follow-up, the cost-effectiveness of screening vs. no intervention was US$ 180/life year gained (LYG).
  • The cost-effectiveness of prophylaxis vs. screening was $ 511/LYG.
  • The cost-effectiveness of prophylaxis vs. screening was estimated at $1538/LYG if the proportion of patients with CD4+ count ≤50 cells/µl decreased by 75%.

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2010 Jun;60(6):474-7 [20347868.001]
  • [Cites] Clin Infect Dis. 2010 Feb 1;50(3):291-322 [20047480.001]
  • [Cites] Clin Infect Dis. 2001 Mar 15;32(6):955-62 [11247718.001]
  • [Cites] Sante. 2001 Jan-Feb;11(1):17-23 [11313228.001]
  • [Cites] Clin Infect Dis. 2002 Jan 15;34(2):277-84 [11740718.001]
  • [Cites] Clin Infect Dis. 2003 Jan 1;36(1):86-96 [12491207.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Feb;19(2):85-90 [12639243.001]
  • [Cites] Int J STD AIDS. 2004 Jan;15(1):48-50 [14769172.001]
  • [Cites] HIV Med. 2004 May;5(3):131-2 [15139976.001]
  • [Cites] J Clin Microbiol. 1991 Aug;29(8):1616-9 [1761681.001]
  • [Cites] Ann Intern Med. 1997 Jun 15;126(12):946-54 [9182471.001]
  • [Cites] Med Decis Making. 1997 Oct-Dec;17(4):373-81 [9343795.001]
  • [Cites] JAMA. 1998 Jan 14;279(2):130-6 [9440663.001]
  • [Cites] J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep;3(3):74-9, 84-5 [15573711.001]
  • [Cites] AIDS. 2005 Jul 1;19(10):1043-9 [15958835.001]
  • [Cites] AIDS. 2005 Aug 12;19(12):1299-308 [16052085.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]
  • [Cites] Clin Infect Dis. 2006 Oct 15;43(8):1069-73 [16983622.001]
  • [Cites] AIDS. 2006 Nov 14;20(17):2183-91 [17086058.001]
  • [Cites] AIDS. 2006 Nov 14;20(17):2199-206 [17086060.001]
  • [Cites] AIDS. 2007 Jan 30;21(3):351-9 [17255742.001]
  • [Cites] Int J Tuberc Lung Dis. 2007 Jul;11(7):747-54 [17609049.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):929-35 [17697087.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):555-9 [17577124.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):644-5 [18362695.001]
  • [Cites] AIDS. 2009 Feb 20;23(4):525-30 [19182676.001]
  • [Cites] Clin Infect Dis. 2009 Apr 1;48(7):856-62 [19222372.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1182-3 [19451796.001]
  • [Cites] Ann Intern Med. 2009 Aug 4;151(3):157-66 [19620143.001]
  • [Cites] Clin Infect Dis. 2009 Sep 15;49(6):931-4 [19681708.001]
  • [Cites] Clin Infect Dis. 2010 Aug 15;51(4):448-55 [20597693.001]
  • (PMID = 21085478.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antifungal Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8VZV102JFY / Fluconazole
  • [Other-IDs] NLM/ PMC2976692
  •  go-up   go-down


90. Friedrichs B, Thiel E: [Relapsed pulmonary lymphomatoid granulomatosis grade III: curative treatment with radioimmune therapy and autologous stem cell transplantation]. Dtsch Med Wochenschr; 2010 Sep;135(38):1857-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relapsed pulmonary lymphomatoid granulomatosis grade III: curative treatment with radioimmune therapy and autologous stem cell transplantation].
  • [Transliterated title] Pulmonale lymphomatoide Granulomatose Grad III: kurativer Therapieansatz mit Radioimmuntherapie und autologer Stammzelltransplantation.
  • INVESTIGATIONS: A chest X-ray and subsequent computed tomography (CT) scans showed a lesion measuring 10×8 cm in the right upper pulmonary lobe.
  • These findings were consistent with lymphomatoid granulomatosis grade III.
  • During remission the previously present lymphoma lesion of the lung was resected.
  • Histology did not reveal any residual active lymphomatoid granulomatosis.
  • CONCLUSIONS: Combination of Y-90 ibritumomab tiuxetan and high-dose chemotherapy followed by ASCT may offer an efficacious and well-tolerated targeted treatment approach for patients with relapsed lymphomatoid granulomatosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lung Neoplasms / therapy. Lymphomatoid Granulomatosis / therapy. Neoplasm Recurrence, Local / therapy


91. Kendi AT, McKinney AM, Clark HB, Kieffer SA: A pediatric case of low-grade lymphomatoid granulomatosis presenting with a cerebellar mass. AJNR Am J Neuroradiol; 2007 Oct;28(9):1803-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pediatric case of low-grade lymphomatoid granulomatosis presenting with a cerebellar mass.
  • Lymphomatoid granulomatosis (LA) is a rare angiocentric lymphoreticular proliferative disease that primarily involves the lungs but may also involve extrapulmonary sites including the central nervous system, skin, and kidneys.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / radiography. Lymphomatoid Granulomatosis / pathology. Lymphomatoid Granulomatosis / radiography

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893222.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Kameda H, Okuyama A, Tamaru J, Itoyama S, Iizuka A, Takeuchi T: Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. Clin Rheumatol; 2007 Sep;26(9):1585-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis.
  • We report on a patient of rheumatoid arthritis (RA) who sequentially developed an axillary mass and a fatal interstitial pneumonia during a 2-year course of methotrexate (MTX) therapy.
  • Autopsy revealed a systemic lymph node involvement and the diagnosis of Epstein-Barr virus (EBV)-related lymphoproliferative disease (LPD) with the features of lymphomatoid granulomatosis was made.
  • This is the first report of a RA patient receiving MTX therapy sequentially developing MTX-associated lymphomatoid granulomatosis and DAD.
  • [MeSH-minor] Aged. Arthritis, Rheumatoid / drug therapy. Fatal Outcome. Humans. Lymphomatoid Granulomatosis / etiology. Male. Pneumonia / chemically induced. Pulmonary Alveoli / pathology. Pulmonary Alveoli / virology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Invest. 1999 Aug;46(3-4):151-8 [10687309.001]
  • [Cites] J Rheumatol. 1987 Dec;14 (6):1164-71 [3325643.001]
  • [Cites] Semin Arthritis Rheum. 1997 Jun;26(6):794-804 [9213378.001]
  • [Cites] Chest. 2003 Jun;123(6):2150-3 [12796204.001]
  • [Cites] Arthritis Rheum. 1996 Feb;39(2):272-6 [8849378.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] J Rheumatol. 1997 Dec;24(12):2299-303 [9415631.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):567-8 [12139747.001]
  • [Cites] Clin Rheumatol. 1997 May;16(3):321-3 [9184276.001]
  • [Cites] Semin Arthritis Rheum. 1987 Feb;16(3):186-95 [3823910.001]
  • [Cites] Arthritis Rheum. 1997 Oct;40(10 ):1829-37 [9336418.001]
  • [Cites] Am J Med. 1995 Sep;99(3):276-81 [7653488.001]
  • [Cites] Rheumatology (Oxford). 2002 Dec;41(12 ):1346-56 [12468813.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3909-15 [12010788.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1740-51 [15188349.001]
  • [Cites] Eur Respir J. 2000 Feb;15(2):373-81 [10706507.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):14-21 [10643695.001]
  • [Cites] Rheum Dis Clin North Am. 1997 Nov;23(4):917-37 [9361161.001]
  • [Cites] J Rheumatol. 1994 Jan;21(1):51-4 [8151587.001]
  • (PMID = 17200802.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


93. Ishii H, Kishi K, Kushima H, Hashinaga K, Umeki K, Ohama M, Tokimatsu I, Hiramatsu K, Kadota J: [Pulmonary lymphomatoid granulomatosis radiologically mimicking interstitial pneumonia]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):483-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary lymphomatoid granulomatosis radiologically mimicking interstitial pneumonia].
  • We report a rare case of pulmonary lymphomatoid granulomatosis radiologically mimicking interstitial pneumonia.
  • A histopathologically diagnosis of pulmonary lymphomatoid granulomatosis (angiocentric immunoproliferative lesion, grade 1) was made by thoracoscopic lung biopsy.
  • [MeSH-major] Lung Diseases / radiography. Lymphomatoid Granulomatosis / radiography
  • [MeSH-minor] Diagnosis, Differential. Herpesvirus 4, Human. Humans. Lung Diseases, Interstitial. Male. Middle Aged. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644945.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. He CN, Zhang J, Duan GC: [Clinicopathological characteristic of lymphomatoid granulomatosis]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):336-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristic of lymphomatoid granulomatosis].
  • [MeSH-major] Lung Neoplasms. Lymphomatoid Granulomatosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antiviral Agents / therapeutic use. Diagnosis, Differential. Granulomatosis with Polyangiitis / diagnosis. Humans. Prognosis. Sarcoidosis / diagnosis. Tuberculosis, Pulmonary / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706144.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antiviral Agents
  • [Number-of-references] 26
  •  go-up   go-down


95. Footracer KG: Immigrant health care in the United States: what ails our system? JAAPA; 2009 Apr;22(4):33-6, 60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immigrant health care in the United States: what ails our system?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452819.001).
  • [ISSN] 1547-1896
  • [Journal-full-title] JAAPA : official journal of the American Academy of Physician Assistants
  • [ISO-abbreviation] JAAPA
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


96. Raja R, Lamont D, Yung A, Solanki K: A can of red herrings. Int J Rheum Dis; 2010 Aug;13(3):e46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomatoid granulomatosis is a rare disease.
  • It is not recognized to be present in lymphoproliferative disease on its own.
  • We report the first case of anti-CCP antibody positivity in lymphomatoid granulomatosis presenting with polyarthritis.
  • This case illustrates the evolving nature of this disease and its characteristics at different stages leading to the challenge of an accurate diagnosis in the setting of a paraneoplastic polyarthritis.
  • [MeSH-major] Arthritis / etiology. Lung Neoplasms / diagnosis. Lymphomatoid Granulomatosis / diagnosis. Paraneoplastic Syndromes / etiology

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704611.001).
  • [ISSN] 1756-185X
  • [Journal-full-title] International journal of rheumatic diseases
  • [ISO-abbreviation] Int J Rheum Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Peptides, Cyclic; 0 / RNA, Viral; 0 / cyclic citrullinated peptide
  •  go-up   go-down


97. Rastawicki W: [Humoral response to recombinant YeuB, Ail, YadA and Inv proteins of Yersinia enterocolitica in patients with yersiniosis]. Med Dosw Mikrobiol; 2009;61(1):21-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Humoral response to recombinant YeuB, Ail, YadA and Inv proteins of Yersinia enterocolitica in patients with yersiniosis].
  • [Transliterated title] Humoralna odpowiedź na rekombinowane białka YeuB, Ail, YadA i Inv pałeczek Yersinia enterocolitica w przebiegu jersiniozy u ludzi.
  • Recombinant YeuB, Ail, YadA and Inv proteins of Y enterocolitica were expressing in E. coli BL21 (DE3) using the pET-30 Ek/LIC expression vector.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517812.001).
  • [ISSN] 0025-8601
  • [Journal-full-title] Medycyna doświadczalna i mikrobiologia
  • [ISO-abbreviation] Med Dosw Mikrobiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Bacterial Proteins; 0 / Immunoglobulins; 0 / Recombinant Proteins; 0 / YadA protein, Yersinia; 0 / YeuB protein, Yersinia enterocolitica; 114073-91-5 / invasin, Yersinia
  •  go-up   go-down


98. Braham E, Ayadi-Kaddour A, Smati B, Ben Mrad S, Besbes M, El Mezni F: Lymphomatoid granulomatosis mimicking interstitial lung disease. Respirology; 2008 Nov;13(7):1085-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis mimicking interstitial lung disease.
  • Lymphoid granulomatosis is a rare form of pulmonary angiitis.
  • This case report presents a patient with lymphoid granulomatosis in whom the clinical presentation, radiological features and the partial response to corticosteroid therapy mimicked interstitial lung disease.
  • Lymphoid granulomatosis was only diagnosed at post-mortem examination.
  • [MeSH-major] Lung Diseases, Interstitial / diagnosis. Lung Neoplasms / diagnosis. Lymphomatoid Granulomatosis / diagnosis
  • [MeSH-minor] Antigens, CD20 / immunology. Biopsy. Bronchoalveolar Lavage. Bronchoalveolar Lavage Fluid / cytology. Bronchoscopy. Diagnosis, Differential. Fatal Outcome. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphocytes / immunology. Lymphocytes / pathology. Middle Aged. Oncogene Proteins, Viral. Tomography, X-Ray Computed. Viral Matrix Proteins / metabolism


99. Fernández de Bobadilla J, López de Sa E, Alonso Troncoso I, Moreno Gómez R, Rubio-Terrés C, Soto Alvarez J: [Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study]. An Med Interna; 2006 May;23(5):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Análisis coste-efectividad del uso de atorvastatina en pacientes diabéticos de tipo 2: modelo farmacoeconómico del estudio CARDS.
  • BACKGROUND AND OBJECTIVE: To perform a cost-effectiveness analysis of the use of Atorvastatin 10 mg in the primary prevention of cardiovascular disease in patients with type 2 diabetes (DM2).
  • In the present cost-effectiveness analysis, effectiveness units were life years gained (LYG) and quality adjusted life years (QALY), obtained from differences in morbimortality and life expectancy in DM2 patients, with and without previous cardiovascular events.
  • RESULTS: Incremental cost-effectiveness ratio of using Atorvastin 10 mg versus placebo was 5,886 euro per LYG and 8,046 euro per QALY.
  • CONCLUSIONS: In the primary prevention of the cardiovascular disease in type 2 diabetic patients, the use of Atorvastatin 10 mg is cost-effective, with a cost per LYG and per QALY below that of other alternatives widely used in the Spanish National Health System, and also below a value considered as a reasonable threshold for our country, which might unofficialy be around 30,000 euro/ QALY.


100. Bäckdahl L, Guo JP, Jagodic M, Becanovic K, Ding B, Olsson T, Lorentzen JC: Definition of arthritis candidate risk genes by combining rat linkage-mapping results with human case-control association data. Ann Rheum Dis; 2009 Dec;68(12):1925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Advanced intercross lines (AIL) between arthritis susceptible DA rats and arthritis resistant PVG.1AV1 rats were injected with differently arthritogenic oils to achieve an experimental situation with substantial phenotypic variation in the rat study population.
  • CONCLUSIONS: High-resolution mapping in AIL populations defines limited sets of candidate risk genes, some of which appear also to associate with RA and thus may give clues to evolutionarily conserved pathways that lead to arthritis.
  • [MeSH-minor] Animals. Case-Control Studies. Crosses, Genetic. Epistasis, Genetic. Genetic Association Studies / methods. Genetic Predisposition to Disease. Genotype. Humans. Phenotype. Polymorphism, Single Nucleotide. Quantitative Trait Loci. Rats. Rats, Inbred Strains. Species Specificity. Terpenes

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066175.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Terpenes; 26HZV48DT1 / pristane
  •  go-up   go-down






Advertisement